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Abstract 
Chemoenzymatic synthesis is a leading technique in the diversification and late stage 
modification of complex molecules, due to the high regio and stereo specificities of the 
enzymes. Over the last decade, the broad aromatic substrate scope for a class of 
prenyltransferases known as aromatic prenyltransferases has been extensively studied.  
Aromatic prenyltransferase catalyzed prenylation reactions are highly prevalent in 
nature and contribute to the amazing structural and functional diversity of natural 
products. Given their natural function and broad aromatic substrate promiscuity, 
aromatic prenyltransferases have been investigated as biocatalytic tool essential to 
facilitate chemoenzymatic natural product diversification.  Although many studies have 
accomplished highlighting the acceptor substrate scope of this class of enzyme none 
have explored the enzyme’s potential to transfer unnatural alkyl groups.  Herein, we 
investigate the alkyl donor specificity of four aromatic prenyltransferases, SirD, 
FgaPT2, NphB and CdpNPT, in combination with our extensive library of synthetic 
alkyl pyrophosphates.  To further highlight the feasibility of aromatic prenyltransferases 
as a powerful biocatalyst, we successfully diversified FDA approved drug compounds, 
subsequently resulting in the improved in vitro activity of the modified compound. 
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Chapter 1: Introduction to Aromatic Prenyltransferases 
Important Natural Products 
Prenylation is ubiquitous across all biological systems and has been known to enhance 
lipophilicity of compounds giving the compounds a stronger affinity to biological 
membranes, as well as altering binding specificity and providing isoprenoid chains to be 
incorporated into the carbon scaffold.  As a result, prenylated natural products display 
different pharmacological activities distinct from their non prenylated precursors 
attracting attention amongst the medical and scientific community (Figure 1)[1]. Indole 
diketopiperazines, derived from L-tryptophan and a second amino acid, typically and L-
proline, L-tryptophan, L-histidine, L-phenylalanine or L-leucine, are a unique class of 
prenylated natural products with a wide spectrum of biological and pharmacological 
activities.[2] This class includes the tryprostatins A and B, nocardioazines, 
fumitremorgin C and Echinulin. Tryprostatin A and B, originally cultured from the 
fungus Aspergillus fumigatus and A. tamari, are found to inhibit cell cycle progression 
of various cancer cell lines.[3] It has been determined that tryprostatin A is active 
against tubulin polymerization, disrupting the interaction between microtuble associated 
proteins (MAP) and the C-terminal domain of tubulin.  Although tryprostatin B also 
arrest cell cycle progression at lower concentrations than tryprostatin A it has a different 
mechanism of action as compared to tryprostatin A.[3] Echinulin and cyclomarazine A 
and B posses biological and pharmacological activites..  Specifically, echinulin and its 
analogues show antiviral, anticancer, and neuroprotective activity.[5][6] Cyclomarazine 
A and B, a reverse N-prenylated compound, has moderate antibacterial activity against 
 
   2 
vancomycin-resistant Entrococcus faecium and methicillin-resistant Staphylococcus 
areus.[7]  
 
Aurachins, a unique family of natural products featuring a quinoline chromophore with 
a C-3 or C-4 farnesyl or geranyl substitution, display multiple biologically active 
properties.[8] Due to their structural similarities to ubiquinol and vitamin K, aurachins 
act as inhibitors of the electron transport chain, specifically by inhibiting various 
cytochrome complexes.  They have been reported to possess strong antimicrobial, 
antifungal and antiplasmodial characteristics. Napyradiomycins, a group of natural 
products isolated from Actinomycetes, were previously identified as antibacterial 
antibiotics; however, they have recently been identified to exhibit cytotoxicity against 
human cancer cell lines.  It has been speculated that the inhibitory effect against 
mitochondrial electron transport thus decreasing ATP production explains their 
mechanism of again against cancer cells.[9, 10] Diazepinomycin, an unusual metabolite 
found in bacterium Micromonospora sp. RV115, features a benzodiazepine derivative 
with a farnesyl side chain and underwent phase II clinical trials for the treatment of 
glioblastoma multiforme. Diazepinomicin inhibits the Ras-MAPK signaling pathway, 
crosses the blood-brain barrier and accumulates in gliomas possibly binding to the 
peripheral benzodiazepine receptor, a component of the mitochondrial permeability 
transition pore which is involved in the regulation and initialization of apoptosis.[11-13] 
Cudraflavone B, a prenylated flavone produced in C. tricuspidata with a long list of 
pharmacological activities such as anti-proliferative, monoamine oxidase (MAO) 
inhibitory effects, apoptotic activity in gastric carcinoma and melanoma cells as well as 
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hepatoprotective activity, neuroprotective effects and reactive oxygen species inhibition 
against glutamate-induced neurotoxicity.[14] Therefore, this natural product has the  
potential to treat neurodegenerative diseases such as Alzheimer’s, Parkinson’s disease, 
ischemia and may prove useful in treating variety of cancers.[15] These compounds 
illustrate the vast structural and pharmacological diversity of prenylated natural 
products. 
 
Figure 1. Prenylated compounds 




   4 
Prenyltransferases 
Prenyltransferases are a large and diverse family of enzymes responsible for catalyzing 
the transfer of prenyl groups onto an assortment of acceptor compounds.[16] Based on 
their biochemical and structural characteristics, as well as their primary amino acid 
sequences, this large family of enzymes is organized into smaller subcategories.  
Isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) are 
products from the mevalonate pathway that can serve as the initial precursors for the 
prenyl pyrophosphate biosynthesis as well as prenyl donors for protein, peptide, tRNA 
and aromatic prenyltransferase enzymes.[17] In the biosynthesis of linear isoprenoids, 
prenyl diphosphate synthases catalyze the transfer of prenyl groups onto alkene carbons 
through sequential condensation reactions of IPP with other prenyl diphosphates[18]. 
Protein prenyltransferases are capable of transferring C15 and C20 carbon chains to 
nucleophilic cysteine residues near the C-terminus of the protein, while peptide 
prenyltransferases of the TruF family catalyze the posttranslational side chain 
prenylation of peptides.[19, 20] Prenyltransferases are also capable of modifying 
nucleic acids found in tRNA by attaching prenyl and geranyl groups onto the amino 
group of adenosine and sulfur atom in 5-methylaminomethyl-2-thiourdine 
nucleotides.[21, 22] Further, a large and well-studied family of aromatic 
prenyltransferase (PT) enzymes catalyze the transfer of prenyl moieties from prenyl 
donors such as dimethylallyl pyrophosphate (DMAPP, C5), geranyl pyrophosphate 
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Aromatic Prenyltransferase 
In nature, aromatic PTs perform prenylation reactions on naphthalene, flavonoid, 
xanthone, coumarin, polyphenol and indole alkaloid aromatic compounds to generate 
multiple secondary metabolites in plants, fungi and bacteria.[23-25] Prenylation can 
occur late or early in the biosynthetic pathway, wherein the prenylated products can be 
further tailored by cyclization, hydroxylation, oxidation or further functionalization. 
Therefore, aromatic PTs contribute to the bioavailability and structural diversity of 
secondary metabolites by increasing the lipophilicity or contributing to the overall 
carbon scaffold. Prenylated secondary metabolites exhibit remarkable biological 
activities, e.g., anti-microbial activity, anti-cancer activity, anti-virus activity, and anti-
oxidant activity[26-28]. Aromatic PTs are capable of performing C-C, C-O, C-N bond 
formation, and in certain conditions C-S prenylation.[12, 29-32] The reactions can take 
place in a forward or “normal” prenylation, where the C1 position of the prenyl donor 
connects directly to the aromatic moiety of the acceptor compound; alternately the 
reactions can take place in a “reverse” manner, where the C3 or tertiary carbon of the 
prenyl donor connects to the aromatic acceptor.[33] This class of enzymes all shares a 
common ααββ structural motif, known as the PT barrel.[34-41]    
Within the large group of soluble aromatic PT enzymes, two main classes exist, the 
super family dimethylallyl tryptophan synthases (DMATS) and the CloQ/NphB 
group.[28, 36, 42-44] The DMATS superfamily is mostly responsible for prenylating 
nitrogen containing compounds such as indole alkaloids and indole alkaloid derivatives 
and are found primarily in fungi although some can be found in bacteria.  Aromatic PTs 
belonging to the CloQ/NphB group utilize aromatic compounds such as phenols, 
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naphthalenes, phenazines, and flavonoids as aromatic substrates and are found in both 
bacteria and fungi.[45] Many of these soluble aromatic PTs exhibit considerable 
substrate promiscuity towards both donor and acceptor compounds accepting unnatural 
and synthetic analogues, a property critical to the development of synthetically useful 
biocatalysts (Figure 2). These enzymes are tools capable of regio-specifically 
functionalizing complex compounds in ways not currently achievable via synthetic 
means. Aromatic PTS are becoming a valuable tool for the late stage modification of 
complex natural and unnatural products, which is useful for the development of novel 
pharmaceutical candidates. 
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Figure 2 . Aromatic prenyltransferase substrates.  





















































































































































































































































cis-indolyl vinyl isonitrile (7)
Substituted Trp (5)
Indolylbutanone (8) Indole (9) Phloroglucinols (10) Naphthols (11) p-hydroxybenzaldehyde(12)
L-tyrosine (13) m-tyrosine (14) o-tyrosine (15) 4-amino-Phe (16) Disperse Violet 1 (17)
Umbelliferone (19) Flavones (22)
Xanthones (26)






























   8 
Global fold and Overall Structure 
Global fold 
To date, all enzymes belonging to the super family of soluble aromatic 
prenyltransferases adopt a similar b-barrel fold found exclusively within this class.[34, 
36, 38, 40, 46-49]  This fold was originally observed in the enzyme NphB, a 
prenyltranserase involved in the biosynthesis of the prenylated polyketide naphterpin in 
Streptomyces sp. Strain CL190.[36] This novel fold, which was termed a PT-barrel, is 
reminiscent of the better-known TIM barrel, which is a (ba)8-barrel fold, but differing 
in the connectivity of the secondary structure elements.[50] The PT-barrel is comprised 
of a cylindrical b-sheet of ten anti-parallel b-strands surrounded by a secondary ring of 
solvent exposed a-helices.  The secondary connectivity forms an AABB repeating 
motif; however, variability exists within known structures of soluble aromatic 
prenyltransferase due to helical kinks, additional helices and b-strands. The ten b-
strands are arranged centrally, in a sequential antiparallel configuration generating a 
generous solvent accessible active site (Figure 3)[51]. 
As stated, most variations of the overall fold can be found within helices and loops 
surrounding the cylindrical b-sheet.  For example, in the structure of EpzP, a phenazine 
prenyltransferase found in Streptomyces cinnamonensis DSM 1042, three additional 
310-helices were found, one of which is located on the resolved C-terminus, owing 
responsibility for sealing up one end of the barrel.[46] Similarly, C-terminal helixes can 
be found on several other PT especially those belonging to the CloQ/NphB family 
(EpzP, FamD1/AmbP3, NphB, CloQ). In the case of CloQ, two a-helixes can be found 
following the final repeating unit; however, from the crystal structure only a11 is 
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covering the opening of the barrel and participating in substrate interactions.[37] 
Moreover, much of the variance in the global fold can be attributed to the overall size 
differences between aromatic PTs. Aromatic PTs range in size from 302 to 464 
residues. The additional residues of the larger enzymes are found in the extended loop 
regions located on either side of the barrel opening.  These regions are typically seen in 
the DMATS superfamily of enzymes such as FgaPT2 and CdpNPT and have been 
shown to exclude the barrel opening and participate in substrate binding.[49] [35] 
 
Figure 3. Ribbon structure of FgaPT2 (PDB ID 314X) 
Ribbon structure of FgaPT2 showing 10 b –strands (yellow) a- helices (red) of the PT-




The overall interior architecture of the b-barrel’s catalytic chamber is shared among the 
enzymes of this class.[35, 47, 52] The central cavity can be separated into three distinct 
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regions. Located at the top of the barrel is the prenyl donor binding pocket, lined with 
basic, positively charged residues, and non-charged polar residues which participate in 
ionic and hydrogen bonding interactions between the sidechains of the residues and the 
negatively charged phosphate moiety of the prenyl donor.  The middle region of the 
cavity possess a conserved cluster of aromatic residues, mainly tyrosine.  The hydroxyl 
group of the tyrosine form a “tyrosine shield”, protecting the allylic cation generated by 
the cleavage of the phosphate group from unwanted nucleophilic attack by solvent 
molecules. The third and bottom region of the cavity is composed mainly of 
hydrophobic residues responsible for the interaction and stability of the aromatic 
acceptor substrate and necessary intermediates. In many structures, the base of the 
barrel is occluded by structural elements such as rigid helices, a-helix or 310-helix, or 
extended loops.[36, 49, 53] The bottom region of the cavity offers the greatest amount 
variability, dictating substrate specificities and well as regio-specificities of the 
prenylated product.    
 
Prenyl Binding Site 
Due to the ubiquitous nature of the pyrophosphate moiety of the donor substrates in 
prenyltransferase reactions, it is not surprising that the residues found in this region are 
highly conserved.  The a- and b-phosphates are anchored by hydrogen bonds with 
water molecules and polar residues as well as ionic interactions with positively charged 
basic residues lowering the ionization energy for the phosphate moiety.[19] Among the 
most structurally conserved residues surrounding the pyrophosphate binding site 
include arginine, lysine, asparagine and glutamine.  The basic residues interact with the 
 
   11 
pyrophosphate group and neutralize the negative charge while the polar residues and 
water mediated interactions fix the substrate into the active site via hydrogen bonding.  
The positively-charged pyrophosphate binding site does differ slightly between the 
magnesium-independent and magnesium-dependent PTs.  It can be seen in the structure 
of NphB, a magnesium-dependent PTs, that two structurally conserved basic residues in 
the magnesium-dependent PT are missing, the loss of the positive charge is 
compensated by a magnesium ion that is coordinately via the aspartate side chain of 
Asp62.[36] Although the majority of the residues participating in the binding of the a- 
and b-phosphate groups are conserved, some variability is found.  Similarly, water 
mediated hydrogen bonding between polar residues and the electronegative oxygen 
atoms is seen in many structures of aromatic PTs but is not strictly conserved 
throughout. [36, 49] A highly structurally and functionally conserved cluster of tyrosine 
and other aromatic residues reside in this location of the active site surrounding the 
bridging oxygen to the prenyl group.  Believed to be responsible for shielding the 
carbocation intermediate of the activated prenyl group, the ring of tyrosine and aromatic 
residues are a catalytic characteristic of all aromatic PTs. [23, 40, 47, 49, 54]Although 
the prenyl donors for aromatic PTs are variable in chain length, upon comparison of the 
structures it is clear that neither the pyrophosphate binding domain nor the “tyrosine 
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Aromatic Binding Site 
Aromatic prenyltransferases are well known for their relaxed substrate specificities.  
[44, 54, 55] Tolerance is attributed to the spacious hydrophobic binding pocket, 
accommodating both the aromatic acceptor substrate and the carbon chain tail of the 
prenyl donor. The pocket is formed by nonpolar and hydrophobic residues of different 
sizes with varied numbers of interactions to the substrate. Structural similarities and 
differences of residues in contact with the substrate are of particular interest, as even 
small changes in the binding pocket have been known to alter the catalytic function. 
[56] Despite obvious differences in substrate specificity and regio-selectivity, residues 
found in the active site of aromatic PTs are relatively similar.   
 
In many cases, the binding site residues remain functionally conserved but differ in the 
size of the amino acid side chain, changing the dimensions of the catalytic chamber.  
This is seen when comparing the acceptor binding site residues of aromatic PTs found 
in the DMATS family members, AtaPT, AnaPT, CdpNPT, FgaPT2 and FtmPT1. [47] 
The residues found in the aromatic acceptor binding pocket of AtaPT have relatively 
short side chains, lending the enzyme one of the largest solvent accessible surface area 
as well as greatest overall volume of the structurally characterized aromatic PTs . For 
example, residues Leu83, Gln172, Ser192 and G251 are found lining the active site of 
AtaPT, whereas the residues in equivalent positions of AnaPT are Phe103, Gln192, 
Phe212 and Phe265. Other spatial differences in the aromatic binding site can be seen in 
CdpNPT upon comparison to FgaPT2.  Residue Thr102 and Arg244 in FgaPT2 are 
replaced with Ala271 and Ala313 in CdpNPT, enlarging the binding site relative to the 
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first. Additionally, positions Phe103, Gly126, Ile266, and Val340 on AnaPT are 
replaced with larger amino acids in CdpNPT corresponding to Leu109, Ala313, Phe272, 
and Met349.  Variation in size of the active site is not limited to indole PT, size 
difference can be seen in the CloQ/NphB family of aromatic PTs as well. The binding 
site of EpzP was found to be larger than that of CloQ when comparing the larger amino 
acids Phe68, Phe161, Tyr233 and Trp295 to those smaller residues Thr64, Thr161, 
Ser236, Leu298 in EpzP. The various sizes of the aromatic binding site can explain the 
catalytic specificities of each PTs towards different aromatic substrates, prenyl donors 
as well as the orientation of the substrate.  
 
 Because the aromatic binding site accommodates both the prenyl chain of the donor 
and the aromatic substrate, and is the most variabile amongst aromatic PTs, the majority 
of mutational studies have focused attention on this region.  Mechanistic mutational 
studies have been conducted to better understand the essential residues required for 
catalysis.  For example, a conserved glutamate residue, found within most indole 
prenyltransferases, was proven to be necessary for catalysis through selective 
mutations.[56] In the case of FtmPT1, single mutant E102Q was generated and 
incubated with its native substrates.  This enzyme variantwas unable to catalyze the 
conversion to tryprostatin B, to the limits of detection, in the presence of the precursor 
compound, brevianamide F.  Interestingly, while both glutamate and glutamine are 
capable of forming hydrogen bonds with the N-1 atom of brevianamide F, only 
glutamate contains a negative charge at that position that can serve as a catalytic base, 
an apparent requirement for catalysis. As a follow up to these results, a similar more 
recent mutational study was performed in bacterial indole PT, AmbP1 which catalysis 
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the magnesium dependent selective C-3 geranylation of 3-((Z)-2’-isocyanoethenyl) 
indole. To study the importance of glutamate at position 209, mutations E209A and 
E209L were generated, thus replacing the carboxyl group with one that lacks hydrogen-
bonding capabilities, and for Leu also or presents a bulkier isopropyl group.  Both 
AmbP1 variants were inactive, further supporting the previous studies results, 
implicating the importance of the conserved glutamate in catalysis. In addition to a 
better understanding of the catalytic mechanism, the mutation of key residues has 
resulted in altered donor and acceptor selectively, increased catalytic abilities, and new 
regio-specificities of enzyme.[38, 39] Recently, a structure-based engineering study was 
conducted on the endophenazine prenyltransferase, EpzP, wherein the active site was 
modeled after a more efficient endophenazine enzyme, PpzP.[47] The resulting single 
residue mutation, A285Q, yielded a 14-fold increase in catalytic activity when 
compared to the wild-type enzyme and a two-fold increase in catalytic activity 
compared to PpzP[46]. Similarly, indolactam prenyltransferases, TleC and MpnD  
which perform the reverse prenylation and geranylation of indolactam V respectively, a 
underwent single, double, and triple mutations switching the preference for either 
geranyl pyrophosphate (GPP) or DMAPP and changing the regio- and stereo- 
selectivity of the enzymes.[53] Mutant K174A of tryptophan prenyltransferase FgaPT2, 
generated through site-directed mutagenesis, was able to switch prenylation positions 
and prenyl attachment from its native C-4 normal prenylation capabilities to C-3 reverse 
reaction [57]. Aromatic PTs are becoming a well-studied biosynthetic enzyme family 
with strong potential for rational design and engineering to further advance the field of 
chemoenzymatic synthesis.   
 
   15 
 
Reactions mechanism 
Despite a diverse substrate scope of aromatic PTs, the catalytic mechanism is expected 
to proceed in a similar manner . Specifically, the mechanism of the alkylation reaction 
has been characterized to proceed via a dissociative SN1- like mechanism involving a 
carbocation-mediated electrophilic aromatic substitution[56, 58, 59]. To discern 
between the dissociative and associative mechanism, positional isotope exchange (PIX) 
experiments were performed using FgaPT2, a magnesium dependent prentyltransferase 
from Aspergillus fumigatus.[58]  In this experiment, DMAPP was synthesized with an 
18O –label on the bridging oxygen between the C1 dimethylally and pyrophosphate 
group [56]. The isotopically label DMAPP was enzymatically reacted with tryptophan 
and partially converted into product. The unreacted starting material was analyzed for 
isotopic scrambling via 31P NMR spectroscopy revealing that 15% of the isotopically 
labelled DMAPP contained the 18O-label in a non-bridging position. These results could 
possibly indicate a carbocation formation stable enough to allow for a P-O bond 
rotation in the active site by which the C-O bond cleavage is a reversible step.  This 
would support a SN1-like dissociative mechanism by which a partially stabilized 
carbocation could proceed forward to form the arenium ion with the aromatic substrate,  
or the reaction could proceed backwards, re-associating with the pyrophosphate group 
to re-form the starting material, DMAPP. To further test the mechanism, a known 
unreactive tryptophan analog, 6-flurotryptophan, was used in the identical PIX 
experiment and revealed a similar ratio of non-bridging to bridging isotopic label in the 
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unreacted starting material. This is believed to further support the existence of a 
carbocation intermediate mediating the stepwise dissociative mechanism. 
 
Solving the crystal structure of aromatic PTs provided further insight into the enzymatic 
mechanism. Structures were solved in the presence of the bound substrates providing a 
snap-shot of the active sight immediately before catalysis. Generally, the pyrophosphate 
prenyl donors, DMAPP or GPP, bind to a highly conserved binding site, comprised 
primarily of positively charged and nonpolar residues, neutralizing the negative charge 
of the pyrophosphate moiety. Most soluble aromatic PTs are metal ion independent, 
excluding NphB who’s prenyl binding site is dependent on the presence of a Mg2+ metal 
ion. Activation of the prenyl moiety involves the release of the pyrophosphate group, 
generating an allylic carbocation intermediate capable of multiple resonance forms 
leading to either a forward (C-2) or a reverse (C-3) addition of the alkyl group. Studies 
have indicated the double bond at the b-position of the prenyl donor is crucial for the 
stability of the carbocation, loss or change location did not yield any product[60].  As 
seen in the crystal structure of both NphB/CloQ and DMATS family of aromatic 
prenyltransferase, the carbon chain moiety of the prenyl donor is sandwiched between a 
conserved tyrosine residue and the aromatic substrate, facilitating the carbocation 
intermediate via stabilizing p-cation interactions and protecting its reaction with 
unwanted nucleophiles including solvents. Key charged residues, such as glutamate and 
lysine, are believed to assist during catalysis participating in deprotonation as the 
substrate undergoes an electrophilic aromatic substitution.  Once the arenium ion is 
formed, the last deprotonation step is thought to be performed either directly by a key 
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residue or via water mediated interactions, restoring aromaticity and yielding the final 
product. 
 
Conclusions and future directions. 
Over the last decade, many advances have been made towards the structural and 
biochemical characterization of aromatic PTs, resulting in over 50 biochemically 
characterized and 14 known structures for the enzymes of this class. This family of 
aromatic PTs has a diverse and vast acceptor substrate scope while also possessing the 
ability to accept multiple non-native substrates as well.  Since aromatic PTs have the 
capability to functionally diversify biologically relevant scaffolds, thus producing 
natural and unnatural products they have the potential to chemoenzymatically 
synthesize a rich and untapped source of biologically and pharmacologically interesting 
compounds.  High structural complexity and limited late stage functionalization 
methods prevent cost effective total synthesis of many natural products, limiting their 
usefulness as pharmaceuticals. Consequently, the high demand for chemo- and regio-
selective catalysts is driving the development of biomimetic chemoenzymatic synthetic 
methodology.  Although much of the proposed utility of aromatic PTs has been directed 
at their promiscuous aromatic substrate scope, we aim to showcase their ability to 
diversity natural products and pharmaceutical compounds through non-native 
alkylation.  The successful utilization of unnatural acceptor and donor substrates with 
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Chapter 2: Determination of Alkyl-Donor Specificity of Tyrosine-O 
Prenyltransferase SirD from Leptosphaeria maculans a 
Introduction 
Sirodesmin PL is a non-host specific phytotoxin produced by the pathogenic fungus 
Leptosphaeria maculans, known for causing the devastating blackleg disease in canola. 
Sirodesmin PL is a member of the epipolythiodioxopiperazine (ETP) class of secondary 
metabolites found in fungi. Like other ETPs, sirodesmin PL features a disulphide bridge 
across a diketopiperazine ring and exhibits antifungal, antibacterial, antiviral 
activities[61-63]. Interest in the properties of this secondary metabolite sparked a drive 
to investigate into the biosynthetic gene cluster and biosynthetic pathway for sirodesmin 
PL, leading to the discovery of a putative prenyltransferase gene sirD[64]. SirD was 
found to be responsible for the O-prenylation of L-Tyrosine in the first pathway specific 
step for the biosynthesis of sirodesminPL (Figure 4)[65] 
 
Figure 4. Sirodesmin biosynthetic pathway. 
Biosynthetic pathway for sirodesmin PL involving SirD in the first committed step of the 
pathway. 
__________________ 
a Reprinted with permission from: John Wiley and Sons and ChemBioChem, Authors 
Chandrasekhar Bandari, Erin M. Scull, Johanna M. Masterson, Rachel H. Q. Tran, Steven B. 
Foster, Kenneth M. Nicholas, and Shanteri Singh. “Determination of Alkyl-Donor Promiscuity 
of Tyronside Prenyltransferase SirD from Leptosphaeria maculans” ChemBioChem 2017, 18 
(23), 2323-2327 DOI 10.1002/cbic.201700469. Copyright 2017 ChemBioChem. Copy-right 
permission has been included in the appendix. 
SirD
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Due to its high sequence similarity to known DMATS enzymes, prenyltransferase SirD 
is presumed to have the characteristic PT-fold, although the structure remains unknown. 
The functionally of SirD is independent of metal cations alike with other indole PTs. In 
addition to its native function in the synthesis of dimethylallyltyrosinde, SirD has been 
shown to accept tryptophan, tryptophan derivatives, tyrosine and tyrosine derivatives 
such as 4-aminophenylalanine, 4-methoxytryptophan, 7-methyltryptophan, 4-
mecraptophenylalanine, and L-3, 4- dihydroxyphenylalanine (Figure 5).[66, 67] 
Through the structural elucidation of the enzymatic products, SirD is capable of 
catalyzing O-, C-, N- and S-, prenylation[30, 66]. Specifically, SirD catalyzes normal S-
prenylation of the sulfhydryl group of mecraptophenylalanine as well as the normal N-
prenylation of the amino group of 4-aminophenylalanine. SirD also catalyzes the N- and 
C- prenylations of tryptophan and tryptophan derivatives with the ability of transferring 
the prenyl group onto three different sites of the indole ring (N1, C6, C7), performing a 
normal prenylation at C6 and a reverse prenylation at C7 and N1. Through these 
studies, it was concluded that the electronic properties of the substituents on the indole 
ring played a role in determining the regio-specificity of the prenylation. Incubation 
with 4-methyltryptophan yielded a normal prenylation at C7 and a reverse prenylation 
at N1, while 4-methoxytrptophan gave a normal and reverse prenylation only a C7. 
Similar to other DMATs[60, 68, 69], SirD catalyzed reactions when incubated with 
unnatural pyrophosphate donors methylallyl pyrophosphate (MAPP), 2-pentenyl 
pyrophosphate (2-pen-PP), and benzyl pyrophosphate[32]. Further, it is believed that 
these studies provide evidence that SirD follows the dissociative electrophilic alkylation 
mechanism proposed for the prenylation by other DMATSs where the orientation of the 
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substrate in the enzymatic active site and electronic effects play a pivotal role in 
determining position and prenylation type.  
 
Figure 5. Products of SirD 





Studies thus far by different groups were focused on investigation of acceptor substrate 
specificity of SirD. These studies have demonstrated that SirD accepts derivatives of L-
Tyr and L-Trp, catalyzing normal (attachment via C1΄ of DMAPP) or reverse 
(attachment via C3΄ of DMAPP)  prenylation of O-, N-, S- and C- nucleophilic centers 
(Figure 5).[30, 66] However, apart from a couple of unnatural alkyl donor (2-pentenyl- 
SirD
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and benzyl- groups[70]) studies, not much is known about the unnatural alkyl-donor 
specificity of SirD. The goal of this study is to understand the alkyl donor specificity of 
SirD. To do this, we assessed the alkyl donor specificity of SirD using 21 synthetic 
alkyl pyrophosphate (alkyl-PP) analogues, performed the kinetic studies and identified 
the regio-specificity of the alkylated products using NMR spectroscopy.  
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Contribution 
In this study, the library of alkyl-donors (Figure 6) was synthesized by Dr. 
Chandrashekar Bandari, Johanna Masterson, and Rachel Tran. The large-scale tyrosine 
alkylation reaction, HRMS analysis and NMR characterization was done by Dr. 
Chandrashekar Bandari. My contributions involve expression and purification of SirD, 
reverse phases high-performance liquid chromatography (RP-HPLC) assessment of 
alkyl-donor specificity of SirD and determination of kinetic parameters for SirD 
catalyzed reaction with diverse alkyl-donors. Most of the contents including text, tables 
and figures for this chapter were directly taken from the publication .[71] 
 
Figure 6. Library of synthetic alkyl-PP  
Pyrophosphate analogues assessed with SirD catalyzed reaction with L-Tyr. 
Results and Discussion 
The recombinant SirD was overexpressed in Escherichia coli BL21(DE3) cells 
transformed with a codon optimized synthetic sirD gene in pET28a vector. The 
 
   23 
resulting SirD with N-terminal His6-fusion protein was purified to homogeneity via Ni-
NTA affinity chromatography. Standard uniform assay conditions (1.2 mM alkyl-PP 
analog, 1 mM L-Tyr, 5 µM SirD, 25 mM Tris, 5 mM MgCl2, 50 mM KCl, pH 7.5, 16 h 
at 35 °C) were adopted to facilitate the assessment of donor substrate specificity of the 
SirD with synthetic alkyl-PP analogues (Figure 6). Production of alkyl-L-Tyr 
derivatives was determined by a RP-HPLC end point assay (Figure 7) with subsequent 
confirmation by HRMS coupled with liquid chromatography (LC) analysis for all 




Figure 7. RP-HPLC chromatograms of SirD catalyzed reactions.  
Reactions were incubated with L-Tyr and alkyl-PP analogues that led to the formation 
of corresponding alkyl- L-Tyr analogues. The remaining L-Tyr and product of the 
reaction are labeled with * symbol and compound number respectively. 
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RP-HPLC and HRMS Studies 
An initial assessment of the SirD catalyzed alkylation of L-Tyr with 21 synthetic alkyl-
PPs based upon RP-HPLC of analytical scale reaction is illustrated in Figure 7, wherein 
16 of 21 synthetic analogues in SirD catalyzed reactions resulted in corresponding 
alkylated L-Tyr products. Fourteen of the 16 positive SirD reactions produced a single 
corresponding mono-alkylated L-Tyr products, whereas, two analogues (A8 and A21) 
resulted in two mono-alkylated L-Tyr products each as confirmed by HRMS analysis 
(Table 1). Of the 21 putative substrates tested with SirD, 9 led to appreciable (>50%) 
production of the corresponding O-alkyl- L-Tyr, an additional 2 led to moderate (25-
50%) conversion, and 5 offered detectable product (<25%) under the conditions 
described (Figures 9 and 10). Except for A7, A12 and A14, all analogues with a double 
bond at the β-position served as substrates. 
 
 
Figure 8. Percent conversion  
Percent conversion of alkyl-PP analogues to the corresponding alkyl-L-Tyr catalyzed 
by SirD based upon RP-HPLC. No product formation was observed in the absence of 
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Table 1. Summary of HRMS data of alkyl-O-Tyr analogues from SirD catalyzed 
alkylation reaction with L-Tyr and synthetic alkyl-PP analogues 
Enzyme Product Chemical Formula Calculated Mass Observed Mass 
A1-Tyr C14H20NO3 [M+H] + 250.1443 250.1446 
A2-Tyr C15H22NO3 [M+H] + 264.1600 264.1599 
A3-Tyr C16H24NO3 [M+H] + 278.1756 278.1756 
A4-Tyr C16H22NO3 [M+H] + 276.1600 276.1585 
A5-Tyr C17H24NO3 [M+H] + 290.1756 290.1757 
A6-Tyr C19H22NO3 [M+H] + 312.1600 312.1599 
A8-Tyr C18H20NO3 [M+H] + 298.1443 298.1444 
A9-Tyr C19H22NO4 [M+H] + 328.1549 328.1553 
A10-Tyr C13H18NO3 [M+H] + 236.1287 236.1274 
A11-Tyr C13H17ClNO3 [M+H] + 270.0897 270.0895 
A13-Tyr C13H18NO3[M+H] + 236.1282 236.1274 
A17-Tyr C14H18NO3[M+H] + 248.1287 248.1283 
A18-Tyr C16H22NO3 [M+H] + 276.1600 276.1605 
A19-Tyr C15H20NO3 [M+H] + 262.1443 262.1443 
A20-Tyr C16H22NO3 [M+H] + 276.1600 276.1604 
A21-Tyr C20H22NO3 [M+H] + 324.1600 324.1597 
 
Kinetic Studies 
The SirD steady-state kinetic parameters for reactions with alkyl-L-Tyr yield > 25% 
were determined based on product formation monitored by HPLC (Table 2, Figure 9). 
Importantly, the KM values for most of the analogues remained similar except for A18, 
where a 5 - 6-fold increase in the KM compared to A20 is observed, likely caused by the 
steric factors in the active site of the enzyme due to the presence of extra terminal 
methyl group. Surprisingly, A11, where an electron withdrawing chloro group replaced 
one of the methyl groups of DMAPP, and A10, which lacks a methyl group of DMAPP, 
were equally efficient (Table 2). However, both A10 and A11 were ~200 fold worse 
compared to the natural alkyl donor, A1, even though their KM was 3 – 4 times lower 
than A1. Interestingly, where direct comparisons could be made, the analogues that 
contained groups to enhance the stability of carbocation[72] via increased conjugation 
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or resonance stabilization correlated with the increased catalytic efficiency. For 
example, the kcat values of the reaction correlated with conjugation by methyl group in 
the order, A1 > A2 > A3 > A10 > A17 (Table 2). Even among the analogues containing 
conjugated double bonds (A17- A20), the increase in the kcat values of the reaction 
correlated with the presence of methyl group in the order, A20 > A19 > A18 > A17 
(Table 2). While the literature precedence suggests cinnamyl carbocations to be highly 
stable,[73] cinnamyl analogues did not serve as good alkyl donors for the SirD reaction 
with L-Tyr. This is likely attributed to the steric hindrance in the active site of the 
enzyme due to the aromatic group in the analog (Table 2). Similar results were obtained 
for other analogues containing aromatic groups. However, the analogues that contained 
a triple bond at the β-carbon (A15 and A16) did not serve as donors, likely due to the 
reduced stability of the carbocation[72] by the attached sp-hybridized alkynyl group in 
addition to the steric requirement of the enzyme. Similarly, the analogues with electron 
withdrawing groups at the β-carbon (A14) did not serve as donors. 
Table 2. Kinetic parameters for SirD with 1 mM L-Tyr and 0.025 - 6 mM alkyl-PP 
analog in 25 mM Tris, 5 mM MgCl2, 50 mM KCl, pH 7.5 at 35 °C. 
 
Alkyl-PP analog kcat (min-1) KM  (mM) kcat / KM (mM-1min-1) 
A1 41 ± 3 0.23 ± 0.06 178 ± 15 
A2 18  ± 2 0.20 ± 0.11 90 ± 31 
A3 3.3 ± 0.2 0.24 ± 0.08 14 ± 3 
A4 0.33 ± 0.02 0.13 ± 0.03 2.5 ± 0.6 
A5 3.5 ± 0.3 0.21 ± 0.05 16 ± 2 
A10 0.060 ± 0.003 0.07 ± 0.06 0.9 ± 0.2 
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A11 0.04 ± 0.02 0.05 ± 0.04 1.0 ± 0.3 
A17 0.05 ± 0.01 0.26 ± 0.07 0.20 ± 0.06 
A18 0.10 ± 0.06 0.73 ± 0.19 0.14 ± 0.02 
A19 0.22 ± 0.08 0.17 ± 0.04 1.3 ± 0.3 
A20 0.74 ± 0.02 0.12 ± 0.05 6.1 ± 0.8 
 
 
Figure 9.  Michaelis-Menten kinetic plots for SirD reactions 
Kinetic parameters detemered by Michaelis-Menten plots with 1mM Tyrosine and 
varying concentrations of pyrophosphate analogues  
kcat = 41 ± 3 min-1
Km = 0.23 ± 0.06 mM
kcat =18  ± 2 min-1
Km =  0.2 ± 0.11 mM
kcat = 3.3 ± 0.2 min-1
Km = 0.24 ± 0.08 mM
kcat =  0.33 ± 0.02 min-1
Km = 0.13 ± 0.03 mM
kcat = 3.5 ± 0.3 min-1
Km = 0.21 ± 0.05 mM
kcat = 0.060 ± 0.003 min-1
Km = 0.07 ± 0.06 mM
kcat = 0.04 ± 0.02 min-1
Km = 0.05 ± 0.04 mM
kcat = 0.05 ± 0.01 min-1
Km = 0.26 ± 0.07 mM
kcat = 0.10 ± 0.06 min-1
Km = 0.73 ± 0.19 mM
kcat = 0.22 ± 0.08 min-1
Km = 0.17 ± 0.04 mM
kcat = 0.74 ± 0.02 min-1
Km = 0.12 ± 0.05 mM
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SirD Structural Model  
In order to understand the alkyl-PP chain-length selectivity by SirD, we generated a 
homology model of SirD based on the template structure of FgaPT2 (PDB accession 
number 3I4X) that covered 92% sequence length of SirD (a.a. 27-440), and shared 30% 
sequence identity and 65% sequence similarity with SirD using SWISS-MODE.[74] In 
the SirD structural model, the L-Tyr and the non-hydrolyzable form of DMAPP 
(DMSPP) were docked posed for catalysis in a similar manner as in other ABBA PT 
structures (Figure 10).[24, 36, 40, 41, 47, 49]  
 
Figure 10: Structural model of SirD.  
Structure is based on the template structure of FgaPT2 (PDB 3I4X) with docked L-Tyr 
(colored in yellow) and dimethylallyl thiopyrophosphate (DMSPP, colored in green). 
Colored in ligh-blue stick models are the active site residues of SirD interacting with 
DMSPP and L-Tyr.  
 
Briefly, the docking of the DMSPP and L-Tyr in the active site of SirD was performed 
to be consistent with the conserved interactions found among the class of ABBA 
PTs.[24, 36, 40, 41, 47, 49] These include hydrogen bonding interactions of the amine 
side chain of conserved basic residues (R126, K209, R282, K284, and K363; Figure 10) 
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and the conserved aromatic residues (Y211, Y 286, Y365 and Y420) positioned to 
shield and stabilize the alkyl carbocation via π-cation interactions (Figure 10). 
Interestingly, according to the SirD model displayed in Figure 10, the distance between 
-OH of L-Tyr and -C1' of DMSPP; as well as C-3 of L-Tyr and -C3' of DMSPP are ~2.6 
Å. While the distance may facilitate either C1¢- normal O-prenylation or C3¢-reverse 
prenylation, the nucleophilicity of the -OH group seems to drive the observed normal 
O-alkylation of L-Tyr by SirD. In the SirD model, the alkyl chain of the natural donor, 
A1 seem to stack on the aromatic ring of the Y365. The current SirD model suggests 
steric clash to be a potential contributing factor to the low or no turn-over of alkyl 
donors containing long carbon chain or bulky aromatic groups. 
NMR Studies 
The SirD alkylation reactions with product yield > 25% were scaled up and purified via 
RP-HPLC to understand the regio-chemistry of alkyl group transfer. Based on the NMR 
characterization of the regiospecificity of SirD catalyzed alkyl-transfer performed by 
Dr. Bandari, all alkyl-L-Tyr (Figure 6, A1, A2, A3, A4, A5, A10, A11, A17, A18, A19, 
A20) were confirmed as O-alkylation of L-Tyr analogues (Figure 11). Additionally, 
SirD produced two mono-alkylated L-Tyr products in the presence of A8 and A21. This 
suggests possibility of alkylation of L-Tyr at other nucleophilic center apart from –OH 
of L-Tyr. Based on the proximity of -C3 of L-Tyr to -C3' of DMSPP in the current SirD 
model (Figure 10), the reverse alkylation at –C3 of L-Tyr seems more likely, in addition 
to the normal O-alkylation. However, a better understanding of the relationship between 
substrate and SirD regioselectivity requires more studies including the crystal structures 
of SirD bound to different substrates.  
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Figure 11. NMR confirmed structures.  
Structures of alkyl-tyrosine products of SirD reaction with alkyl-PP analogues 
determined by NMR. 
 
Conclusions 
In summary, the presented work demonstrates the pliable nature of SirD towards a wide 
range of allylic alkyl donors, which is expected to be further expanded via enzyme 
engineering. In addition, our work also demonstrates SirD to catalyse mostly 
regiospecific, normal O-alkylation of L-Tyr. Thus, these studies highlight the potential 
utility of SirD for chemoenzymatic differential alkylation of natural products and open 
the door for interrogation of the alkyl donor specificity of other prenyltransferases. 
Experimental 
Unless otherwise stated, all chemicals and reagents were purchased from Sigma-Aldrich 
(St. Louis, MO, USA), Acros (New Jersey, USA), Alfa-Aesar (Ward Hill, MA, USA) 
or TCI (Portland, OR, USA) and were reagent grade or better. PD-10 column and Ni-
NTA superflow columns were purchased from GE Healthcare (Piscataway, NJ). 
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General methods 
All reactions were conducted in oven- or flame-dried glassware under a nitrogen 
atmosphere with anhydrous solvents, unless otherwise noted. Reactions were monitored 
by thin-layer chromatography (TLC) (EMD Millipore Corp, Billerica, MA, USA) and 
visualization was accomplished with UV light (254 nm) followed by staining with 
phosphomolybdic acid solution or anisaldehyde solution and heating. Flash column 
chromatography was performed using ACS grade solvents and silica gel (SiliCycle Inc, 
P60, particle size 40-63 µm). HPLC was accomplished using Agilent 1220 system 
equipped with a DAD detector.  Method A (HPLC): To monitor SirD reactions, 
analytical reverse-phase (RP) HPLC employed a Gemini-NX, C-18 (5 µm, 4.6 mm × 
250 mm) column (Phenomenex, Torrance, California, USA) [gradient of 1% B to 10% 
B over 10 min, 10% B to 50% B over 5 min, 50% B to 100% B for 12 min, 100% B to 
1% B over 1 min, 1% B for 7 min (A = ddH2O with 0.1% TFA; B = acetonitrile) flow 
rate = 1 mL min-1; A220]. The reaction was monitored by the retention time difference 
between starting material and product. Method B (HPLC): Semi-preparative RP HPLC 
was conducted on a Gemini-NX, C-18 (5 µm, 10 mm × 250 mm) column (Phenomenex, 
Torrance, California, USA) to purify the L-Tyr analogues [gradient of 1% B to 10% B 
over 10 min, 10% B to 50% B over 5 min, 50% B to 100% B for 12 min, 100% B to 1% 
B over 1 min, 1% B for 7 min (A = ddH2O with 0.1% TFA; B = acetonitrile) flow rate = 
2 mL min-1; A220]. High-resolution mass spectrometric (HRMS) data and liquid 
chromatography mass spectrometric (LCMS) were obtained on Agilent 6545-QTOF 
W/1290 HPLC mass spectrometer at the University of Oklahoma, Department of 
Chemistry and Biochemistry.  
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Overexpression and purification of SirD 
The Leptosphaeria maculans SirD in pET28a vector bearing N-terminal-His6 fusion 
was provided by Prof. Jon Thorson (University of Kentucky). Recombinant SirD with 
N-terminal-His6 (herein referred to simply as SirD), was expressed in a E. coli 
BL21(DE3) host in the presence of 50 µg mL-1 of kanamycin at 37 °C to an OD600 of 
~0.6, reduced the temperature to 20 °C, induced with 0.5 mM IPTG, and continued to 
grow at 20 °C for another 16 h. The cells were harvested by centrifugation (30 min, 
5000 rpm), resuspended in buffer A (20 mM NaH2PO4, 300 mM NaCl, 10 mM 
imidazole, pH 7.8). The cells were lysed for 30 min on ice by sonication (Fisher 
Scientific Model FB505; Thermo Fisher Scientific, Waltham, MA; 500 W, 4 x 30 s 
pulses, ~1 min between pulses) on ice.  SirD was purified via affinity chromatography 
(5 mL HiTrap Ni-NTA chelating column, GE Healthcare, Piscataway, NJ) following 
standard linear gradient (50 mM NaH2PO4, 300 mM NaCl, pH 8.0 with a linear gradient 
of imidazole of 10-500 mM) using an NGC™ liquid chromatography systems (Bio-
Rad, USA). Buffer exchange of pooled fractions containing the purified protein was 
accomplished using a PD-10 column (GE Healthcare) eluted with 25 mM Tris-HCl, 50 
mM KCl, pH 8. Protein concentrations were determined by Bradford assay (Bio-Rad, 
Hercules, CA, USA) using BSA as a standard. All studies were conducted with SirD, 
that retained the N-terminal-His6 affinity tag.  
In-vitro SirD assay 
In vitro SirD reactions were conducted in a volume of 20 µl with 1.2 mM alkyl-
pyrophosphate analog (compound A1 – A21), 1 mM L-Tyr and 5 µM purified SirD in 
25 mM Tris buffer pH 8.0, 5 mM MgCl2, 50 mM KCl, incubated at 35 °C for 16 h. 
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Reactions were quenched by adding an equal volume of methanol followed by 
centrifugation (10,000 x g for 15 min) to remove the precipitated protein and product 
formation for each reaction was subsequently analyzed by RP-HPLC using method A. 
For each reaction, percent yield was based upon the integration of species at 254 nm 
and calculated by dividing the integrated area of product by the sum of integrated area 
of product and/or and the remaining substrate. All putative products were subsequently 
confirmed by HRMS with positive (+) and/or negative (-) mode. Kinetic parameters 
were assessed using 1 mM L-Tyr and variable alkyl-PP analogues (0.1 - 5 mM). Assays 
were conducted in triplicate and all rates were confirmed to be linear. The kinetic 
curves were fit to Michaelis-Menton kinetics using Prism 5.04 (GraphPad Software, 
Inc. La Jolla, CA 92037 USA).  The reactions with > 25% product yield were scaled 
(>500 µM L-Tyr), purified by semi-prep HPLC using method B and the putative new 
products were confirmed by NMR.  
SirD structural model 
 A SirD BLAST search against the structural database, PDB revealed SirD to have 30% 
sequence identity with Trp-C4-PT, FgaPT2 (PDB 3I4X). A SirD homology model was 
constructed based upon FgaPT2 using Swiss-Model.[74] Atomic coordinates of the 
ligands, L-Trp and DMSPP were obtained from FgaPT2 structure (PDB 3I4X). L-Tyr 
model was generated by manual editing of the L-Trp using the builder module of PyMol 
(http://www.pymol.org) with no additional energy minimization performed on the 
structures. Both L-Tyr and DMSPP were subsequently modeled in the active site of 
SirD in a manner consistent with the conserved interactions observed for other ABBA-
PTs. [24, 36, 40, 41, 47, 49] The conserved interactions used for modeling-in the 
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ligands include the stacking interaction of L-Tyr with the prenyl moiety of DMSPP and 
the hydrogen bonding interactions of amine side chain of conserved basic residues 
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Chapter 3. Determination of Alkyl-Donor Specificity of a Tryptophan-
C4- Prenyltransferase FgaPT2 from Aspergillus fumigatus.b 
Introduction 
Filamentous fungi, such as Aspergillus, possess some of the most impressive chemical 
factories known in biology and are an incredible source of biologically active natural 
products.[27] Even more, their natural products are being used as scaffolds for more 
focused diversity oriented pharmacological and drug libraries.[75] In the biosytnthesis 
of ergot alkaloids, DMATS has been identified to catalyze the first pathway-specific 
reaction, attaching a prenyl moiety onto L-tryptophan.[76] In 2005 a DMATS gene 
fgaPT2, was identified in the genome sequence for A. fumigatus. FgaPT2 is a soluble 
indole PT responsible for catalyzing the transfer of a prenyl group onto the C-4 position 
of L-tryptophan, which is the first step in the biosynthesis of many indole alkaloids such 
as the fumigaclavines (Figure 12).[77] This prenyl group can then be incorporated into a 
polycyclic carbon scaffold giving rise to diverse active natural products. 
 
Figure 12. The role of FgaPT2 in fumigaclavine C biosynthesis 
__________________ 
b Reprinted with permission from: Royal Society of Chemistry and MedChemComm, Authors 
Chandrasekhar	Bandari,	Erin	M.	Scull,	Tejaswi	Bavineni,	Susan	L.	Nimmo,	Eric	D.	Gardner,	Ryan	C.	
Bensen,	Anthony	W.	Burgett	and	Shanteri	Singh. “FgaPT2, a biocatalytic tool for alkyl-
diversification of indole natural products” MedChemComm 2019, MD-RES-03-2019-
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FgaPT2 is the first DMATS structure to be solved, shortly after the bacterial aromatic 
PT enzyme NphB structure was published.[36] FgaPT2 shares the PT barrel fold, 
common among all aromatic PTs, which contains 5 repeating ααββ units. The 
significant differences between NphB and FgaPT2 structures can be found in the 
connecting extended loop regions and extra α-helices in FgaPT2. The structure of 
FgaPT2 complexed with the native substrate tryptophan and DMSPP revealed the 
architecture of the catalytic binding site and insight into understanding the mechanism 
of alkylation (Figure 13). L-tryptophan binds to a mostly hydrophobic pocket, forming a 
hydrogen bond between the indole NH and E89. [35] This likely enhances the reactivity 
toward the carbocation by stabilizing the positively charged intermediate. This 
hydrogen bond combined with several others is responsible for orienting the tryptophan 
within the catalytic chamber, ultimately determining its regioselectivity. Tryptophan 
forms hydrogen bonds with the side chains of Y191 and R244, and with main chain 
atoms of I80 and L81.[35] The basic side chain on K174 is located perfectly to help 
abstract the proton after C4 alkylation.  Divalent cations Mg2+ and Ca2+ enhance the rate 
of FgaPT2 but are not required.[77] The negative charge of the pyrophosphate binds to 
the positively charged residues R100, K187, R257, K259, and R404.  The oxygen atoms 
are able to hydrogen bond with Y189, Y261, Y345, Y413, and Q343 (Figure 14).[35] 
The carbocation that is formed is stabilized by the π electrons of the substrate indole 
ring and Y345. The carbocation is shielded from reacting with water by Y189, Y261, 
Y345, Y398, and Y413.[35] 
 
   37 
  
Figure 13. Active site of FgaPT2 
 DMSPP in the active site side chains binding with pyrophosphate moiety. Residues in 
the active site interacting with  L-tryptophan and carbon chain of DMSPP[35] 
 
In addition to its native catalytic function, FgaPT2 also accepts a variety of alternative 
substrates (Figure 16). For example, the enzyme can transfer a prenyl group to the 3 
position of tyrosine, the 5 position of ortho-tyrosine, and the 4 and 6 position of meta-
tyrosine.[78] Tyrosine and 4-amino-phenylalanine are accepted by FgaPT2 resulting in 
C3 prenylation, 6.2% and 67% yield respectively.[79] Indole-3-propionic acid and L-β-
homotryptophan were C4 prenylated by whole cells overexpressing FgaPT2.[80] Cyclo-
L-homotryptophan-D-valine was well accepted as a substrate resulting in a 1:1 ratio of 
C4 and C5 prenylated products.[81] 1-naphthol has also been successfully prenylated 
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Figure 14.  Accepted aromatic substrates by FgaPT2. 
Known reactions catalyzed by FgaPT2 and non-native substrates  
DMAPP is the natural donor substrate for FgaPT2, however a couple of unnatural 
pyrophosphates have been successfully transferred using this enzyme.  
Monomethylallyl pyrophosphate (MAPP) gave a 1:1 mixture of C4 and C5 alkylated 
tryptophans, while 2-pentenyl pyrophosphate alkylated the 5 position exclusively.[60] 
Benzyl pyrophosphate was also a substrate for FgaPT2 when incubated with tryptophan 
analogues, result in predominantly in C5 benzylation. The only 5 substituted indole 
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cannot accept GPP or FPP as donors, however certain mutants have been engineered to 
accept longer chain donors.  The FgaPT2 M328G/R244Q mutant was able to geranylate 
cyclo-L-Trp-L-Trp at the C4 position.[84] Met328 plays a major role in determining the 
maximum size of the donor molecule, with many of the smaller side chain mutants 
(C,A,T,S,G,V,N) having significant activity with GPP. FgaPT2 M328A was also able to 
accept FPP, although with very low turnover.[85] Site saturation mutagenesis was done 
on T102, K174, and R244 in attempt to increase the catalytic efficiency of FgaPT2 and 
alter substrate specificity.[86, 87] FgaPT2 K174F had almost no tryptophan activity but 
efficiently C3 prenylated L-tyrosine.[79] The related double mutants K174F/R244X 
(X= L,N,Q,Y) were able to reverse prenylate L-Trp cyclic dipeptides at the C3 position, 
resulting in cyclization (Figure 15).[87] FgaPT2 mutants R244N, R224L, R224Y and 
R244Q had substantially higher activity on a variety of L-Trp cyclic dipeptides while 
maintaining C4 prenylation selectivity.[86] The R244L mutant had the best overall 
substrate tolerance, converting 20-50% of most dipeptides screened. R244Y was the 
only mutant particularly good at prenylating cyclo-L-Trp-L-Phe.[86] FgaPT2 mutants 
K187E, K259E, and R257G all had >95% reduced activity because these residues are 
known to interact with the diphosphate group.[88] 
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Figure 15. FgaPT2 mutants reactions. 




Studies thus far have revealed that FgaPT2 has a broad and diverse acceptor substrate 
scope including, substituted tryptophans, L-Trp containing cyclic dipeptides, isomers of 
L-tyrosine, indolocarbazoles, as well as phenolic molecules.[78, 89-94] A few 
alternative alkyl donors have also been reported with FgaPT2 including the C10 geranyl 
pyrophosphate (GPP), 2-butenyl pyrophosphate, 2-pentenyl pyrophosphate, and benzyl 
pyrophosphate.[60, 68] Based on our recent studies using tyrosine-O-prenyltransferase, 
SirD that demonstrated relaxed alkyl-donor substrate specificity, [95] in this chapter we 
describe the alkyl-donor substrate scope of FgaPT2 using 34 synthetic allylic, and 
benzylic alkyl donors with varying carbon chain length, and substituents. The alkyl 
donor analogues include 21 allylic analogues described in Chapter 2, and 13 additional 
benzylic analogues. For the sake of the flow of the manuscript (submitted to 
MedChemComm) all analogues have been renumbered as described in Figure 16. The 
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HRMS studies, systematic analysis of kinetic parameters and identification of the regio-
specificity of the alkylated products using NMR spectroscopy. 
Contribution 
The library of alkyl-donors (Figure 16) was synthesized by Dr. Chandrashekar Bandari, 
Johanna Masterson and Rachel Tran. The large-scale tryptophan alkylation reaction and 
HRMS analysis was carried out by Dr. Chandrashekar Bandari, NMR characterization 
of alkyl-tryptophan products was performed by Dr. Bandari and Dr. Susan Nimmo. My 
contributions involve expression and purification of FgaPT2, RP-HPLC based 
assessment of alkyl-donor specificity of FgaPT2, and determination of kinetic 
parameters for FgaPT2 catalyzed reaction with diverse alkyl-donors. Most of the 
contents including text, tables and figures for this chapter were directly taken from the 
manuscript submitted for publication to MedChemComm. 
Results and Discussion 
In order to assess the ability of FgaPT2 to accept diverse unnatural alkyl-PP analogues, 
the recombinant FgaPT2 was overproduced in Escherichia coli BL21(DE3) cells 
transformed with codon-optimized synthetic FgaPT2 gene in pET28a vector. The 
resulting FgaPT2 with N-terminal His6-fusion protein was purified to homogeneity via 
Ni-NTA affinity chromatography as described previously,[40] yielding ~40 mg L-1 of 
pure N-terminal His6-fusion protein.  
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Figure 16. Synthetic alkyl-PP analogues used in this study. 
 
RP-HPLC and HRMS Studies 
Standard uniform assay conditions (1.2 mM alkyl-PP analog, 1 mM L-Trp, 5 µM 
FgaPT2, 25 mM Tris, 5 mM MgCl2, 50 mM KCl, pH 7.5, 16 h at 35 °C) were adopted 
to facilitate the initial assessment of donor substrate specificity of the FgaPT2 with 
synthetic alkyl-PP analogues. Production of alkyl-L-Trp derivatives was determined by 
the difference in the retention time of L-Trp and alkyl-L-Trp product using a reverse 
phase high-pressure liquid chromatography (RP-HPLC) endpoint assay (Figure 17) with 
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subsequent confirmation by HRMS coupled with liquid chromatography (LC) analysis 
for all positive reactions (Table 3) to afford complete analysis of the desired product.   
 
Figure 17. RP-HPLC chromatograms of FgaPT2 catalyzed reactions.  
FgaPT2 was incubated with L-Trp and alkyl-PP analogues that led to the formation of 
corresponding alkyl-L-Trp analogues. The peak at retention time 10 min is L-Trp and 
the product peaks are after 15 min in the chromatograms respectively. 
 
   44 
Table 3. Summary of HRMS data of alkyl-Trp analogues.  
FgaPT2 catalyzed alkylation reaction with L-Trp and synthetic alkyl-PP analogues. The 
subscript ‘2’ represents the second product based on HPLC retention time.  
Enzyme Product Chemical Formula 
Calculated 
Mass (Da) 
Observed Mass  
(Da) 
A1-Trp C16H21N2O2 [M+H]+ 273.1603 273.1602  
A2-Trp C17H23N2O2 [M+H] + 287.1760 287.1754 
A3-Trp C18H25N2O2 [M+H] + 301.1916 301.1916 
A4-Trp C18H23N2O2 [M+H] + 299.1760 299.1756 
A4-Trp2 C18H23N2O2 [M+H] + 299.1760 299.1761 
A5-Trp C18H23N2O2 [M+H] + 299.1760 299.1768 
A6-Trp C19H25N2O2 [M+H] + 313.1916 313.1913 
A6-Trp2 C19H25N2O2 [M+H] + 313.1916 313.1911 
A7-Trp C15H19N2O2 [M+H] + 259.1447 259.1449 
A7-Trp2 C15H19N2O2 [M+H] + 259.1447 259.1444 
A8-Trp C15H18ClN2O2 [M+H] + 293.1057 293.1061 
A8-Trp2 C15H18ClN2O2 [M+H] + 293.1057 293.1062 
A9-Trp C15H18BrN2O2 [M+H] + 337.0552 337.0552 
A9-Trp2 C15H18BrN2O2 [M+H] + 337.0552 337.0547 
A10-Trp C14H17N2O2 [M+H] + 245.1290 245.1294 
A13-Trp C20H21N2O2 [M+H] + 321.1603 321.1601 
A14-Trp C21H23N2O3 [M+H] + 351.1709 351.1711 
A15-Trp C21H23N2O2 [M+H] + 335.1760 335.1757 
A16-Trp C26H25N2O2 [M+H] + 397.1916 397.1912 
A17-Trp C16H19N2O2 [M+H] + 271.1447 271.1442 
A17-Trp2 C16H19N2O2 [M+H] + 271.1447 271.1444 
A18-Trp C18H23N2O2 [M+H] + 299.1760 299.1768 
A19-Trp C17H21N2O2 [M+H] + 285.1603 285.1602 
A19-Trp2 C17H21N2O2 [M+H] + 285.1603 285.1605 
A20-Trp C18H23N2O2 [M+H] + 299.1715 299.1751 
A20-Trp2 C18H23N2O2 [M+H] + 299.1715 299.1749 
A21-Trp C22H23N2O2 [M+H] + 347.1760 347.1767 
Ar1-Trp C18H19N2O2 [M+H] +  295.1447 295.1430 
Ar3-Trp C19H21N2O3 [M+H] + 325.1552 325.1547 
Ar4-Trp C19H21N2O3 [M+H] + 325.1552 325.1540 
Ar6-Trp C18H18FN2O2 [M+H] +  313.1352 313.1338 
Ar7-Trp C18H18ClN2O2 [M+H] + 329.1057 329.1039 
Ar8-Trp C18H18BrN2O2 [M+H] + 373.0552 373.0531 
 
The initial assessment of FgaPT2 catalyzed alkylation of L-Trp with 34 synthetic alkyl-
PP analogues based upon RP-HPLC of analytical scale reaction is illustrated in Figure 
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17, wherein 25 of the 34 synthetic analogues (Figure 16) in FgaPT2 catalyzed reaction 
produced corresponding alkyl-L-Trp. All products were subsequently confirmed to be 
mono-alkylated products from HRMS coupled with liquid chromatography (LC) 
analysis (Table 3).  
 
 
Figure 18: The percent conversion of alkyl-PP analogues.  
Percent conversion of alkyl-L-Trp catalyzed by FgaPT2 based upon RP-HPLC. 
Reactions were performed with 1.2 mM alkyl-PP analog, 1 mM L-Trp, 5 µM FgaPT2, 
25 mM Tris, 5 mM MgCl2, 50 mM KCl, pH 7.5, 16 h at 35 °C. No product formation 
was observed in the absence of FgaPT2 or alkyl-PP analog. The blue, green, yellow, 
and black colors in the bar diagram denote C4, C5, C3, and N1 alkyl-L-Trp regio-
isomers as confirmed by NMR, whereas the red color represents alkyl-L-Trp isomer 
with undetermined regio-chemistry. 
 
Of the 25 positive reactions, 12 led to appreciable (>50%) conversion, an additional 
seven led to moderate (20-50%) conversion, while six offered detectable product 
formation (<5%) under the conditions described (Figures 19 and 20). Analysis of HPLC 
and HRMS results suggested more than one product for eight (Figure 18, A4, A6–A9, 
A17, A19, A20) of the 19 analytical scale reactions with product yield > 20% (Figure 
16, A1–A9, A17–A20, Ar1, Ar3, Ar4, Ar6–A8). Notably, the 3-carbon allyl 
pyrophosphate A10 was accepted as a substrate although with a very low conversion 
rate of 1%, resulting in the formation of allyl-L-Trp. However, A11 with a methyl 
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group substituted at the β-carbon of allyl pyrophosphate was not accepted by FgaPT2. 
No product formation was observed for A12 that has a carbonyl group at β-carbon. The 
bulky cinnamyl analog (A13) and its derivatives (A14, A15, A16, and A21) produced 
only a trace amount of the alkylated product with low yield (< 2%). In addition, while 
o-methoxy (Ar3), m-methoxy (Ar4) and p-halogen (Ar6-Ar8) substituted benzyl 
analogues were accepted by FgaPT2, introduction of bulky groups at the para-position, 
including p-methoxy (Ar2), p-methyl (Ar5), p-nitro (Ar9) and di- and tri-substituted 
benzyl analogues (Ar10 – Ar12, and A13) did not serve as substrates for FgaPT2 
catalyzed reaction with L-Trp due to the potential steric hindrance in the active site of 
the enzyme. These results suggest the FgaPT2 catalyzed reaction with L-Trp is 
sterically limited by bulky substitution on the alkyl-donor. 
Kinetic studies 
Michaelis−Menten kinetic parameters for all 19 alkyl-PP analogues with product 
conversion > 20%, (Table 4) and for L-Trp with representative alkyl-PP analogues were 
carried out. The kinetic parameters, rates (kcat) and Michaelis constants (KM) were 
determined from a nonlinear regression fit of initial velocities versus concentration of 
alkyl-PP analog by GraphPad Prism 5.04 (Figure 19) . Interestingly, the KM of L-Trp for 
FgaPT2 with various alkyl-PP donors did not change drastically by the nature of the 
alkyl donors and remained within the range of 0.20 ± 0.08 mM. Consistent with our 
previous observations with tyrosine-O-prenyltransferase SirD,[95] the alkyl-PP 
analogues that contained groups to enhance the stability of the carbocation via increased 
conjugation and resonance stabilization correlated with the increased turnover of the 
product. For example, the kcat values of the reaction correlated with conjugation by a 
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methyl group in the order, A1 > A2 > A3 > A7 (Table 4). In addition, the KM values 
increased with the increased length of the carbon chain in the order A1 < A2 @ A3 @ A5 
< A6 and A17 < A18 @ A19 @ A20. Removing one methyl group of A1 decreased the 
efficiency (kcat/KM) of A7 by 88-fold compared to A1. 
Table 4. Kinetic parameters for FgaPT2 with L-Trp. 
1.2 mM L-Trp, and varied concentration of alkyl-PP analogues in 25 mM Tris, 5 mM 
MgCl2, 50 mM KCl, pH 7.5, 35 °C. (*Relative catalytic efficiency is defined as the 
percent kcat/KM when compared to A1)  
Alkyl-PP analog Kcat  (min-1) KM (mM) kcat / KM  
(mM-1min-1) 
Relative catalytic efficiency*  
A1 50 ± 1 0.14 ± 0.01 357 100 
A2 9.9 ± 0.4 0.48 ± 0.06 21 5.88 
A3 6.5 ± 0.1 0.37 ± 0.02 18 5.04 
A4 0.160 ± 0.006 0.16 ± 0.02 1 0.28 
A5 5.04 ± 0.18 0.31 ± 0.03 16 4.48 
A6 3.2 ± 0.4 1.4 ± 0.2 2.28 0.64 
A7 0.57 ± 0.02 0.14 ± 0.01 4.07 1.14 
A8 1.3 ± 0.1 0.53 ± 0.08 2.5 0.70 
A9 0.47 ± 0.01 0.35 ± 0.03 1.3 0.38 
A17 26 ± 1 0.66 ± 0.06 39 10.92 
A18 28 ± 1 1.1 ± 0.1 25.5 7.14 
A19 20.2 ± 0.9 1.3 ± 0.1 15.5 4.34 
A20 16.9 ± 2 1.39 ± 0.2 12.1 3.39 
Ar1 1.36 ± 0.02 0.22 ± 0.01 6.2 1.74 
Ar3 1.93 ± 0.05 0.57 ± 0.04 3.4 0.95 
Ar4 0.170 ± 0.005 0.73 ± 0.06 0.23 0.064 
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Figure 19. Michaelis-Menten inetic plots for FgaPT2 reactions 
Kinetic parameters detemered by Michaelis-Menten plots with 1mM tryptophan and 
varying concentrations of pyrophosphate analogues incubated at 35°C 
 
Ar6 0.276 ± 0.004 0.4 ± 0.02 0.69 0.19 
Ar7 0.196 ± 0.004 0.43 ± 0.03 0.46 0.13 
Ar8 0.134 ± 0.003 0.32 ± 0.03 0.42 0.12 
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Further, changing one or both methyl groups of A1 to an ethyl group (A2 and A3) 
lowered the enzyme efficiency 17-20 times compared to A1. Similarly, the kcat values of 
the reaction correlated with resonance stabilization in the order A17 > A7; Ar1 > A4; 
Ar1 > Ar6 > Ar7 > Ar8. Furthermore, a 9-fold higher kcat value of Ar1 compared to 
A4 suggests resonance stabilization of the carbocation by the benzylic group contributes 
to the rate of the reaction. However, the kcat value of the cyclohexyl (A4) and benzyl 
analogues (Ar1) were nearly 310 and 36, fold lower than A1. When an electron 
withdrawing group such as chloro (A8) or bromo (A9) replaced one of the methyl 
groups of A1, the efficiency of the enzyme was lowered nearly 150–250 fold compared 
to the natural alkyl donor, A1, which explains the importance of methyl group in 
stabilizing the carbocation. Surprisingly, the dienyl analogues (A17, A18, A19, and 
A20) displayed relatively higher rates with just ~2 fold lower kcat values compared to 
the natural alkyl donor, A1, implying extended resonance stabilization of the 
carbocation favors the FgaPT2 catalyzed reaction. However, the KM values of the dienyl 
analogues were 5-10-fold higher than the natural alkyl donor, A1 and the trend of KM 
values correlated with the increasing length of the carbon chain (C5–C7), in the order, 
A17 < A19 < A20, again pointing at the steric factors and the orientation of the alkyl 
group in the active site of the enzyme to contribute to the enzyme efficiency. All mono-
substituted benzylic analogues (Ar3, Ar4, Ar6, Ar7, Ar8) displayed a similar KM 
value, which was 2–3 fold higher than the benzyl analog, Ar1. The 10-fold higher kcat 
value of o-methoxy (Ar3) compared to the m-methoxy (Ar4), suggests benzylic cation 
stabilization by an o-methoxy group increases the efficiency of the FgaPT2 catalyzed 
alkylation reaction. Among the para-substituted halogens, the kcat values followed the 
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order p-fluoro (Ar6) > p-chloro (Ar7) @ p-bromo (Ar8), suggesting a combination of 
steric factors and possible stabilization of carbocation of the Ar6 carbocation via back 
donation of the non-bonded electron pairs of the fluorine atom to the Ar6 carbocation 
through effective 2p-2p orbital interaction. The observed kcat values of para-substituted 
halogens were ~5-10 fold lower than Ar1, which is consistent with the inductive effect 
of the halogens. Surprisingly, while the para-substituted halogens were accepted by 
FgaPT2, the p-methoxy and p-methyl were not substrates for FgaPT2 catalyzed reaction 
even with their ability to contribute to the stabilization of the benzylic cation, likely due 
to the steric factors in the active site of the enzyme. These results emphasize the fact 
that the FgaPT2 catalyzed Friedel-Craft alkylation reaction proceeds via stabilized 
carbocation,[60] and the steric factor and the orientation of alkyl group in the active site 
has a major role in the ability of FgaPT2 to utilize alkyl donors. 
NMR Studies 
To assess the regio-specificity of FgaPT2 catalyzed alkyl-transfer, the 19 analytical 
scale reactions with an alkyl-tryptophan yield > 20% (reaction involving A1-A9, A17-
A20, Ar1, Ar3 Ar4, Ar6-Ar8, Figure 16) were scaled up, purified via RP-HPLC, and 
characterized via 1H and 2D NMR experiments by Dr. Chandrashekar Bandari. While 
eight of the 19 alkyl-transfer reactions involving alkyl donors A4, A6, A7, A8, A9, 
A17, A19 and A20 yielded two or more mono-alkylated products based on RP-HPLC 
and HRMS analysis, regio-specific alkyl-group attachment of minor products of 
reactions involving A6, A8, A9, A17, A19, and A20 could not be obtained due to 
insufficient intensity of NMR signals. The regiospecificity of 21 alkyl-tryptophan 
analogues was determined using detailed 2D NMR analysis (Figure 20). Among the 21 
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alkyl-tryptophan analogues characterized by NMR , the alkyl group of seven were at C4 
(derived from A1-A5, A7, and Ar3), 11 at C5 (derived from A4, A6, A7, A8, A9, A18, 
Ar1, Ar4, Ar6-Ar8), one at C3 (derived from A17) forming hexahydro-pyrroloindoline 
product as verified by UV (Figure 21), and two were at the N1 (derived from A19, A20) 
position of tryptophan respectively (Figure 20).  
 
 
Figure 20. NMR characterized structures  
Structure of isolated alkyl-tryptophan products obtained from FgaPT2 reaction with L-
Trp and alkyl-PP analogues determined by NMR analysis. 
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Figure 21: UV absorption spectra of L-Trp and C3-A17-Trp.  
Showing signature absorption maxima for hexahydro-pyrroloindoline tryptophan 
product. 
 
Intriguingly, apart from the strict C4 alkylation of tryptophan by FgaPT2 using the 
natural alkyl donor A1, the unnatural alkyl donors, A2, A3 and A5, which contained an 
ethyl group (A2 and A3) in place of one or both methyl group/s of A1, or the similarly 
sized conformationally restricted cyclopentyl analog (A5) selectively added the alkyl 
group at the C4 position of tryptophan. Alkyl-PP analogues with smaller alkyl chain in 
the linear direction compared to A1 (A4 and A7) resulted in a mixture of C4 and C5 
regio-isomers, and alkyl-PP analogues with a methyl group of A1 replaced with a 
halogen (A8 and A9) or larger alkyl chain (A6 and A18) predominantly produced the 
C5 alkylated product. While most of the unnatural benzylic analogues (Ar1, Ar4, Ar6, 
Ar7, and Ar8) produced selectively C5 alkylation of tryptophan, the o-methoxy benzyl 
analog (Ar3) produced a single C4-alkylated tryptophan. Careful analysis of the C4 
alkylating analogues (A1, A2, A3, A5, and Ar3) suggests that C4 substitution is 
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preferred when the carbon chain length is less than 6 while C3’ is also disubstituted to 
facilitate stacking interaction with the indole ring. Therefore, the active site steric 
factors in combination with improper stacking interaction of the alkyl group with the 
indole ring conceivably displaces the carbocation resulting in a direct addition of alkyl 
group to C5 of tryptophan as seen for 11 of the C5-alkyl-Trp products. The addition of 
alkyl groups at the C5 position of tryptophan by most of the alkyl-PP analogues is 
consistent with the orientation of DMASPP with respect to the indole ring in the active 
site of the FgaPT2 crystal structure,[51] where C5 of tryptophan is just at 3.5 Å from 
the C1' of the alkyl group compared to a distance of 3.8 Å between C4 of tryptophan to 
the C1' of the alkyl group (Figure 22).  
 
 
Figure 22: The active site of FgaPT2 structure (PDB:3I4X)  
FgaPT2 in complex with L-Trp and DMASPP displaying distances between C1′ of 
DMASPP and C4 and C5 of L-Trp; and C3′ of DMASPP and C3 of L-Trp. 
 
Conclusions 
In conclusion, this work has revealed that FgaPT2 has a remarkable ability to accept 
diverse allylic and benzylic unnatural alkyl-donor substrates. While FgaPT2 can 
transfer alkyl groups at C4, C5, N1 and C3 position of L-Trp, the C5 position is the 
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preferred alkylation position for FgaPT2 with unnatural alkyl-donors. Thus, these 
studies highlight the potential utility of FgaPT2 for broader applications such as alkyl-
diversification of indole-containing natural products for drug discovery and other 
synthetic applications. Future enzyme mutational studies along with substrate 
engineering is expected to drive the development of more efficient and selective 
FgaPT2-based biocatalysts.  
Experimental 
General materials  
Unless otherwise stated, all chemicals and reagents were purchased from Sigma-Aldrich 
(St. Louis, MO, USA), Acros (New Jersey, USA), Alfa-Aesar (Ward Hill, MA, USA) 
or TCI (Portland, OR, USA) and were reagent grade or better. PD-10 column and Ni-
NTA superflow columns were purchased from GE Healthcare (Piscataway, NJ).  
General methods  
HPLC was accomplished using Agilent 1220 system equipped with a DAD detector. 
High-resolution mass spectrometric (HRMS) data and liquid chromatography mass 
spectrometric (LCMS) were obtained on Agilent 6545-QTOF W/1290 HPLC mass 
spectrometer at the University of Oklahoma, Department of Chemistry and 
Biochemistry. NMR spectra were obtained on Varian VNMRS 400 or 500 MHz 
instruments at the NMR facility of the Department of Chemistry and Biochemistry at 
the University of Oklahoma using 99.9% DMSO-d6 with 0.05% v/v TMS, or 99.9% 
D2O or 99.8% MeOH-d4, 99.9% Acetone-d6 (Cambridge Isotope Laboratories, MA, 
USA. 
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In-vitro FgaPT2 assay 
The recombinant FgaPT2 was overproduced in Escherichia coli BL21(DE3) cells 
transformed with codon-optimized synthetic FgaPT2 gene in pET28a vector. The 
resulting FgaPT2 with N-terminal His6-fusion protein was purified to homogeneity via 
Ni-NTA affinity chromatography as described previously.[40] In vitro FgaPT2 
reactions were conducted in a volume of 20 µl with 1.2 mM alkyl-PP analog (A1 – A21, 
Ar1 – Ar13), 1 mM L-Trp and 5 µM purified FgaPT2 in 25 mM Tris buffer pH 7.5, 5 
mM MgCl2, 50 mM KCl, incubated at 35 °C for 16 h. Reactions were quenched by 
adding an equal volume of methanol followed by centrifugation (10,000 xg for 15 min) 
to remove the precipitated protein and product formation for each reaction was 
subsequently analyzed by RP-HPLC using Method A or Method C. For each reaction, 
percent yield was based upon the integration of species at 254 nm and calculated by 
dividing the integrated area of the product by the sum of the integrated area of product 
and/or and the remaining substrate. All putative products were subsequently confirmed 
by HRMS with positive (+) and/or negative (-) mode. Kinetic parameters were assessed 
using 1.2 mM L-Trp and variable alkyl-PP analogues (0.1 - 6 mM). Assays were 
conducted in triplicate and all rates were confirmed to be linear. The kinetic curves 
were fit to Michaelis-Menton kinetics using Prism 5.04 (GraphPad Software, Inc. La 
Jolla, CA 92037 USA). The reactions with > 20% product yield were performed in 2-5 
mL volume under standard condition, purified by semi-prep HPLC using Method B 
and the putative new products were confirmed by NMR. Method A: To monitor 
FgaPT2 reactions of L-Tryptophan, analytical reverse-phase (RP) HPLC employed a 
Gemini-NX, C-18 (5 µm, 4.6 mm × 250 mm) column (Phenomenex, Torrance, 
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California, USA) [gradient of 10% B to 25% B over 10 min, 25% B to 100% B over 15 
min, 100% B for 3 min, 100% B to 10% B over 0.1 min, 10% B for 7 min (A = ddH2O 
with 0.1% TFA; B = acetonitrile) flow rate = 1 mL min-1; A254]. The reaction was 
monitored by the retention time difference between starting material and product. 
Method B :Semi-preparative RP HPLC was conducted on a Gemini-NX, C-18 (5 µm, 
10 mm × 250 mm) column (Phenomenex, Torrance, California, USA) to purify the L-
Trp analogues [gradient of 10% B to 25% B over 10 min, 25% B to 100% B over 15 
min, 100% B for 3 min, 100% B to 10% B over 0.1 min, 10% B for 7 min (A = ddH2O 
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Chapter 4. Alkyl donor specificity of a Naptherpin prenyltransferase, 
NphB 
Introduction 
NphB, previously referred to as orf2, is a soluble aromatic PT with significant Mg2+ 
dependent activity found in the Naphterpin biosynthetic pathway.[96] Naphterpin is a 
powerful antioxidant produced in the microorganism Streptomyces sp CL190. The core 
is comprised of a naphthoquinone moiety with an attached 10-carbon geranyl group 
forming a cyclohexene ring with a geminal dimethyl group.[97] Briefly, the 
biosynthesis begins with the polyketide 1,3,6,8-tetrahydroxynaphthalene (THN), 
formed from the malonyl-CoA by a type III polyketide synthase, which undergoes an 
oxidative transformation to flaviolin. The resulting THN, flaviolin, or THN-derived 
metabolite are tailored by addition of a geranyl co-substrate and further modified by 
subsequent cyclization. The gene cluster responsible for naphterpin production revealed 
an open reading frame (orf2) with a high degree of homology to the characterized PTs 
CloQ and NovQ, leading to the proposal that orf2 encodes for the PTase responsible for 
the transfer of the geranyl group on THN or THN derivative (Figure 23). [36] Although 
the precise native substrate of NphB currently remains ambiguous, in common practice 
1,6 dihydroxynapthalene is used as a surrogate acceptor substrate. 
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Figure 23. NphB catalyzed step in the biosynthesis of naptherpin[36] 
 
As mentioned, the true biological substrate has not been identified; however, various 
aromatic acceptors have been tested revealing a highly promiscuous nature towards 
aromatic substrates. Initially, enzyme activity was assessed by incubating with prenyl 
donors, DMAPP, GPP, or FPP, in the presence of aromatic acceptors; further, this was  
later tested with an azido-substituted GPP.[36, 54] For the isoprenoid pyrophosphate 
substrates, NphB did not display any enzymatic activity with DMAPP, as isoprenoid 
pyrophosphate substrate. There was detectable activity with FPP and azido-GPP and the 
highest activity with GPP.[36, 98]  
NphB has been assayed for utilization of various aromatic substrates including 
flavonoids, isoflavonoids, plant polyketides and 1,3,6,8-tetrahydroxynaphthalene 
(THN) analogues.  The enzyme is capable of GPP additions on several positions of the 
aromatic ring including C- and O- geranylations yielding several different alkylated 
products.  A comparison of the reaction products showed that most contain a geranyl 
group in the ortho position relative to the hydroxyl group.[54, 99] With the flavonoids, 
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naringenin and apigenin and the C8 position of daidzein[36, 54].  This demonstrates 
that, consistent with other PTs, NphB catalyzes donor-dependent prenylation reactions. 
The structure of NphB consists of a single domain PT- fold with some variability in the 
overall aabb repeating motif resulting in missing the a9 helix between strands b8 and 
b9. Additionally, NphB has three helices outside of the PT-fold. The first helix, 310, is 
found between b1- b2 strands and positioned above the metal binding site within the 
barrel. The second additional helix follows the end of strand b4 and partially overlaps 
with the opening at the C-terminal end of the b-barrel. NphB also has an extra C-
terminal a-helices, that fully extends across the aromatic binding domain opening of the 
barrel. The interior of the barrel contains a number of hydrophobic residues used to 
sequester the geranyl tail of GPP, with the head groups positioned towards the polar end 
of the barrel thus allowing contact with the coordinated Mg2+ cation.  Notably, the 
sequence does not contain the (N/D)DXXD recognition motif found in most Mg2+ 
dependent isoprenoid diphosphate enzymes. 
 
Research Objective 
The aim of this study is to define the alkyl pyrophosphate donor scope of the polyketide 
prenyltransferase NphB, using an extensive synthetic library of 65 pyrophosphate 
analogues, in the presence of the native substrate 1,6-DHN or of the drug compound 
sulfabenzamide. The library includes 44 new synthetic analogues added from the work 
reported in Chapter 3, and all analogues have been renumbered as described in Figure 
24. In this chapter we report an extensive alkyl pyrophosphate donor scope of 
polyketide prenyltransferase NphB with 1,6-DHN and sulfabenzamide, and structure-
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based engineering of NphB.  Interestingly, a comparison of the in vitro activity assays 
with 1,6-DHN or with sulfabenzamide indicated a strong donor dependent alkylation 
reaction.  In the presence of 1,6-DHN or sulfabenzamide, NphB was able to 
catalytically transfer 26 and 29 out of the 65 diverse pyrophosphate donors, 
respectively.  Through the structural elucidation of the alkyl-diversified sulfabenzamide 
compounds, we observed a previously unreported functionality of NphB to perform 
regio specific N-alkylations. Moreover, we accomplished structure-based rational 
engineering of NphB to increase substrate acceptance capabilities, producing a 
gernalyated sulfabenzamide derivative. 
Contributions 
All alkyl pyrophosphate analogues were synthesized by Dr. Chandrasekhar Bandari, 
Tejaswi Bavineni, Johanna Masterson, Rachel Tran, and Eric Gardener. Large-scale 
enzymatic reaction and subsequent purification was carried out in part by me and 
Andrea Batchev. Structural characterization of sulfabenzamide derivatives by NMR 
spectroscopy was performed in part by me, Dr. Susan Nimmo and Andrea Batchev. My 
contributions also involved expression and purification of NphB , RP-HPLC and HRMS 
based assessment of alkyl-donor specificity of NphB, and determination of kinetic 
parameters for NphB catalyzed reaction with diverse alkyl-donors. Some contents from 
this chapter including text, tables and figures will be directly used for a publication in a 
peer-reviewed journal. 
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Results 
Description of the alkyl pyrophosphate library. 
In this study, we investigated the NphB catalyzed alkylation reaction of 1,6-DHN and 
sulfabenzamide, an antimicrobial compound with promising anti-tumor/ anti-cancer 
properties[96], against an internally-generated library of synthesized pyrophosphates. 
The library contains 65 electronically and structurally diverse compounds, designed to 
probe the donor permissiveness of the enzyme as well as potentially generating 
compounds with increased bioactivity (Figure 24).  We have organized the compounds 
according to their chemical space and potential functionality, including; allylic-, 
benzylic- and heterocyclic analogues as well as analogues with chemo selective 
functionally.    
Compounds were designed with two different chemical handles; allylic analogues (PP1-
PP35) and benzylic analogues (PP36-PP48). Amongst the allylic analogues, features 
including chain length, methylation positions, cyclization, degree of saturation, and 
functional groups were varied. In order to better understand the effect of chain length on 
substrate preference, compounds were synthesized with various lengths ranging from an 
allyl pyrophosphate (C3) (PP1) to farnesyl pyrophosphate (C15) (PP35).  Derivatives of 
dimethyl allyl were created with assorted terminal saturated aliphatic chains (PP6-
PP12), altering the overall length as well as bulk of the donor compound. Presumably, 
the saturated carbon chains could add more flexibility to the general structure when 
compared to polyunsaturated chains. Further, carbocation stability of the activated 
allylic group was investigated through conjugated system and the loss of the C3 methyl 
group, thought to stabilize the carbocation through hyper-conjugation.  The necessity of 
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this methyl on the C3 carbon was investigated by either removal (PP3, PP14, PP16, 
PP17, and PP26-PP28), rearrangement on the C2 carbon position (PP4, PP15, PP18) 
or by replacement by a chloro- (PP22) or bromo- (PP23) halogen atom.  Additionally, 
conjugated compounds were synthesizing in either linear (PP13-PP18) or aromatic 
(PP24-PP28) form.  Our library also includes several geranyl derivatives, formed by the 
addition of a methyl group (PP31), ester linked benzyl group (PP33), alcohol group 
(PP34) or alkene group (PP32) on the terminal methyl.  Additionally, a subset of the 
library consists of benzylic analogues substituted with either electron-donating (methyl 
or methoxyl) or electron-withdrawing (fluoro-, chloro-, bromo- or nitro-) substituents. 
To investigate the reactivity influenced by substituent orientation and degree of 
substitution, we synthesized ortho- and meta-methoxy (PP38 and PP39), di-methoxy 
(PP45 and PP46), di-fluoro (PP48)  and tri methoxy (PP48) derivatives on the benzyl 
ring.  
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Figure 24. Library of synthetic alkyl-PP analogues.  
Analogues were assessed with NphB catalyzed reaction with 1,6-DHN or 
sulfabenzamide 
 
Figure 25. Percent conversion.  
Percent conversion of library of alkyl pyrophosphate using 1,6-DHN (blue) or 
sulfabenzamide (orange). Assays were performed under standard condition, 1.2 mM 
alkyl pyrophosphate, 1 mM sulfabenzamide or 1,6-DHN, NphB, 25 mM Tris pH 7.8 
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Table 5. Summary of HRMS data of 1,6-DHN analogues from NphB catalyzed 
alkylation reaction with 1,6-DHN and synthetic alkyl-PP analogues. 
Enzyme Product Chemical Formula 
Calculated 
Mass (Da) 
Observed Mass  
(Da) 
1,6-DHN C10H8O2 [M-H]- 159.0452 159.0457 
1,6-DHN-PP5 C15H16O2 [M-H]- 227.1078 227.1079 
1,6-DHN-PP6 C16H18O2 [M-H]- 241.1234 241.1237 
1,6-DHN-PP8 C17H20O2 [M-H]- 255.1390 255.1394 
1,6-DHN-PP10 C18H22O2 [M-H]- 269.1547 269.1548 
1,6-DHN-PP11 C19H24O2 [M-H]- 283.1703 283.2645 
1,6-DHN-PP16 C16H16O2 [M-H]- 239.1078 239.1081 
1,6-DHN-PP17 C17H18O2 [M-H]- 253.1234 253.1230 
1,6-DHN-PP18 C17H18O2 [M-H]- 253.1234 253.1238 
1,6-DHN-PP19 C17H18O2 [M-H]- 253.1234 253.1235 
1,6-DHN-PP20 C18H20O2 [M-H]- 267.1391 267.1379 
1,6-DHN-PP24 C20H18O2 [M-H]- 289.1234 289.1232 
1,6-DHN-PP28 C21H18O2 [M-H]- 301.1234 301.1235 
1,6-DHN-PP29 C20H24O2 [M-H]- 295.1703 295.1704 
1,6-DHN-PP30 C18H20O2 [M-H]- 267.1390 267.1391 
1,6-DHN-PP31 C21H26O2 [M-H]- 309.1860 309.1859 
1,6-DHN-PP32 C23H28O2 [M-H]- 355.2016 355.2098 
1,6-DHN-PP33 C27H30O3 [M-H]- 401.2122 401.2132 
1,6-DHN-PP34 C20H24O3 [M-H]- 311.1653 311.1660 
1,6-DHN-PP35 C25H32O2 [M-H]- 363.2329 363.2339 
1,6-DHN-PP37 C18H16O3 [M-H]- 279.1027 279.1026 
1,6-DHN-PP54 C18H14O4 [M-H]- 293.0819 293.0821 
1,6-DHN-PP56 C16H17N3O2 [M-H]- 282.1248 282.125 
1,6-DHN-PP61 C18H18O2 [M-H]- 265.1234 265.1244 
1,6-DHN-PP62 C18H18O3 [M-H]- 281.1183 281.1179 
1,6-DHN-PP64 C20H16O3 [[M-H]- 303.1027 303.1031 
1,6-DHN-PP65 C23H26O3 [M-H]- 349.1809 349.1801 
   
Chemoenzymatic syntheses of alkylated 1,6 dihydroxy naphthalene 
NphB was heterologously expressed in Escherichia coli BL21 (DE3) cells as a N-
terminal His-tagged fusion protein and purified to homogeneity by Ni-NTA affinity 
chromatography. Although the true native substrate for NphB is unknown, 1,6-DHN is 
used as a surrogate substrate to assess donor specificity. The purified recombinant 
 
   65 
enzyme was incubated with 1,6-DHN and the synthesized alkyl pyrophosphate donors 
at standard assay conditions (1.2mM alkyl-PP, 1mM aromatic acceptor, 50uM NphB, 
25mM Tris, 5mM MgCl2, 50mM KCl, pH 7.8, 16 h at 35 C). The formation of alkylated 
products was analyzed using reverse phase high-performance liquid chromatography 
(RP-HPLC) and confirmed by high resolution mass spectroscopy (HRMS) (Figure 25 
and 28; Table 5). 
Analysis of the analytical scale reactions demonstrated that 27 of the 65 pyrophosphate 
analogues were able to be catalytically transferred by NphB onto the aromatic substrate, 
1,6-DHN (Figure 25).  Although the HRMS data indicates only monoprenylated 
products for all of the reactions, the HPLC chromatograms for 20 of the 27 catalyzed 
reactions indicated the presence of three different isomer products based off their 
retention times. Similarly, previous studies have determined the formation of three 
different geranylated products upon the incubation of NphB with 1,6-DHN and 
GPP[54].   
Of the 26-catalyzed reaction 16 displayed significant product formation (>20%) and six 
showed a >50% product formation. The six highest producing reactions included the 
native substrate GPP (PP29), PP10, PP30-PP32 and PP34. As expected, the reaction 
containing GPP significant conversion of 75% when incubated for 16h. Both PP10 
(58% conversion) and PP30 (51% conversion) are seven carbons in length and show a 
similar product conversion, PP10 is a butane derivative of DMAPP and PP30 is a 
butene derivative with a terminal alkene. PP31 and PP32 both have added aliphatic 
groups onto the terminal methyl of GPP. Interestingly, PP31 with an additional methyl 
added and was able to show 90% product conversion, overall greater conversion 
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compared to the native substrate, GPP. However, PP32 with an additional terminal allyl 
group, resulted in a decreased the conversion to only 57%.  Analogue PP34 features a 
terminal alcohol group on the geranyl tail and displays an impressive 52% product 
conversion.  
The remaining 10 compounds that showed an appreciable >20% conversion have a 
large distribution in the length of the alkyl moiety.  The smallest compound that was 
catalytically transferred onto 1,6-DHN was an the allylic cyclopentane (PP19 (21%)), 
while the longest were the ether linked benzyl GPP derivative (PP33 (39%)) and FPP 
(PP35 (30%)).  FPP has previously been reported has a substrate for 1,6DHN[36] and 
showed a 30% conversion when incubated for 16h under the stated assay conditions.  
Additional allylic analogues, PP6, PP11, PP18, and PP24 showed 20%, 29%, 21%, 
43% conversion respectively.  PP6 is an ethyl DMAPP derivative, P11 is a pentyl 
DMAPP derivative, while PP18 is a C2 methylated 2,4-hexadiene.  PP24, like PP18, 
has a conjugated system; however, it is in the form of a benzyl substituted DMAPP and 
mediated twice the product conversion compared to PP18. Furthermore, three propargyl 
containing analogues (PP61, PP62 and PP65), ranging in linear length between 7 and 
12 atoms, displayed appreciable conversion. PP61 is a propargyl derivative of DMAPP 
with a terminal propargyl group showing and it underwent a 21% conversion.  Both 
PP62 and PP65 are ether linked propargyl derivatives of DMAPP and GPP 
respectively, PP62 underwent 20% conversion while PP65 had a 33% conversion.      
The remaining enzyme reactions produced <20% conversion. They included allylic 
analogues of varying length, methylation and conjugation; PP5 (DMAPP) (8%), PP8 
(12%), PP12(11%), PP16 (7%), and PP17 (13%). Additionally, PP20, allylic 
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cylcohaxane, and PP28, five-carbon chain aromatic displayed 16%, and 9% conversion. 
Of the 13 synthesized benzyl analogues only one was accepted as substrate; PP37, a 
para-methoxy substituted benzyl analogue, with a 18% conversion.  Two additional 
chemoselective analogues, PP64, a para-propargyl ether substituted benzyl compound, 
and PP56, an azido DMAPP derivative showed slight product formation at  9% and 5% 
respectively.  Finally, only one heterocycle analogue was accepted using 1,6-DHN as 
the  substrate, PP54, a piperonyl pyrophosphate baring a 3, 4 methylene dioxy moiety, 
which exhibited a 14% conversion. 
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Figure 26 RP- HPLC chromatograms. 
RP- HPLC chromatogram of incubation mixtures of 1,6-DHN with pyrophosphate 
analogues which lead to the NphB catalyzed formation of alkylated sulfabenzamide 
derivatives. The peak at approximately 9.5 min is 1,6-DHN and the product peaks are 
after 10 min in the chromatogram. 
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Chemoenzymatic syntheses of alkylated sulfabenzamide 
Next, to investigate the utility of NphB to perform catalytic modification of synthetic 
aromatic substrates, 11 known drug compounds (amoxicillin, methotrexate, tamoxifen, 
catharanthine, puromycin, camptothecin, yohimbine, sulfadoxin, chloramphenicol, 
ethynylestradiol and sulfabenzamide) containing aromatic moieties were incubated with 
prenyl pyrophosphates GPP and DMAPP.  The HPLC and HRMS analysis of the 
enzyme reaction revealed that NphB accepted sulfabenzamide as a prenyl acceptor.  In 
contrast to the native behavior of NphB, no product formation was detected with GPP 
as the donor substrate when sulfabenzamide is the aromatic acceptor.  On the other 
hand, DMAPP was able to be catalytically transferred onto sulfabenzamide producing a 
prenylated derivative.  The drastic shift in donor substrate preference prompted us to 
test the catalytic capability of NphB to transfer non-native alkyl pyrophosphates using 
our library of synthetic pyrophosphates, generating sulfabenzamide derivatives with 
potentially altered biological activity.  
Similar to the analytical reactions involving 1,6-DHN aromatic acceptor, analysis of the 
product formation was performed using HPLC and HRMS. This revealed that 29 out of 
the 65 alkyl-PP enzymatic reactions resulted in alkylated sulfabenzamide products 
(Figure 25 and 29; Table 6).  A variety of distinctive analogues were accepted as alkyl 
donors; markedly, of the 29 accepted donors, less than 50% were seen to be accepted 
using 1,6-DHN.  Overall, the linear length of the accepted donors ranges from a four-
carbon chain (PP5 (DMAPP) (60%), PP19 (100%) and PP3 (4%)) to a seven-carbon 
chain (PP10) (20%)).  Of the 29 positive reactions, ten pyrophosphate analogues (PP5, 
PP6, PP19, PP21, PP14, PP10, PP8, PP40, PP49, PP54) show an appreciable (>20%) 
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product conversion.  Notably, of the analogues showing greater than 20% product 
conversion, half of these contain an aromatic (PP40 (25%), PP54 (46%), and PP49 
(20%)) or non-aromatic ring structures (PP19 (100%) and PP21 (40%)). The remaining 
five analogues contain various carbon chain length, methylation and conjugation.  
Diversity in the overall chain length can be seen in the acceptance of a four-carbon 
chain DMAPP (PP5) and the allylic cyclopentane (PP19), five-carbon chain ethyl 
DMAPP derivative (PP6), and isopropyl DMAPP derivative (PP8 (27%)), and a seven-
carbon chain, butyl DMAPP derivative (PP10 (20%)) donor substrates. The C3 methyl 
group can be found on PP5, PP6, PP10 and PP8.  Compound PP14 (25%) lacked 
methyl groups; however, it is the only analogue to show appreciable product formation 
with a linear conjugated system. Analysis of the subset of benzyl pyrophosphate 
analogues revealed that NphB is capable of transferring eight out of the 13 benzyl 
groups onto sulfabenzamide, including; a para- (PP37 (13%)) and ortho- (PP38 (8%)) 
methoxy substituted benzyl compounds, a para- methyl substituted benzyl compound 
(PP40(25%)), fluorine, chlorine and bromine halogenated benzyl compounds (PP41 
(6%), PP42 (14%), PP43(9%)), para- and ortho- methoxy di-substituted benzyl 
(PP45(11%)), and a para- and meta-methoxy di-substituded benzyl (PP46(8%)).  
Additionally, four aromatic heterocycle analogues; thiopene (PP49(20%)), furane 
(PP50(14%)) a benzothiophen (PP52(11%)) and piperonyl pyrophosphate baring a 3, 4 
methylene dioxy moiety (PP54(46%)) pyrophosphate were also able to be transferred 
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Table 6. Summary of HRMS data of sulfabenzamide analogues from NphB 
catalyzed alkylation reaction with sulfabenzamide and synthetic alkyl-PP 
analogues. 
Enzyme Product Chemical Formula Calculated Mass (Da) 
Observed Mass  
(Da) 
Sulfabenzamide C13H12N2O3S [M+H]+ 277.0641 277.0648 
Sulfabenzamide-PP3 C17H18N2O3S [M+H]+ 331.1111 331.1120 
Sulfabenzamide-PP5 C18H20N2O3S [M+H]+ 345.1267 345.1276 
Sulfabenzamide-PP6 C19H22N2O3S [M+H]+ 359.1424 359.1442 
Sulfabenzamide-PP7 C20H24N2O3S [M+H]+ 373.158 373.1592 
Sulfabenzamide-PP8 C20H24N2O3S [M+Na]+ 395.1406 395.1395 
Sulfabenzamide-PP9 C21H26N2O3S [M+Na]+ 409.1562 409.1576 
Sulfabenzamide-PP10 C21H26N2O3S [M+Na]+ 409.1562 409.1577 
Sulfabenzamide-PP11 C22H28N2O3S [M+Na]+ 423.1719 423.1733 
Sulfabenzamide-PP13 C19H20N2O3S [M+H]+ 357.1267 357.1270 
Sulfabenzamide-PP14 C18H18N2O3S [M+H]+ 343.1111 343.1118 
Sulfabenzamide-PP16 C19H20N2O3S [M+H]+ 357.1267 357.1277 
Sulfabenzamide-PP17 C22H22N2O5S [M+H]+ 371.1424 371.1432 
Sulfabenzamide-PP18 C20H22N2O3S [M+H]+ 371.1424 371.1435 
Sulfabenzamide-PP19 C20H22N2O3S [M+Na]+ 393.1249 393.1266 
Sulfabenzamide-PP20 C21H24N2O3S [M+H]+ 385.158 385.1590 
Sulfabenzamide-PP21 C20H22N2O3S [M+H]+ 371.1424 371.1435 
Sulfabenzamide-PP29 C23H28N2O3S [M+Na]+ 435.1719 435.1723 
Sulfabenzamide-PP30 C21H24N2O3S [M+Na]+ 407.1406 407.1420 
Sulfabenzamide-PP37 C21H20N2O3S [M+Na]+ 419.1036 419.1029 
Sulfabenzamide-PP38 C22H20N2O3S [M+H]+ 393.1267 393.1275 
Sulfabenzamide-PP40 C21H20N2O3S [M+Na]+ 403.1093 403.1106 
Sulfabenzamide-PP41 C20H17FN2O3S [M+Na]+ 407.0842 407.0858 
Sulfabenzamide-PP42 C20H17ClN2O3S [M+Na]+ 423.0546 423.0553 
Sulfabenzamide-PP43 C20H17BrN2O3S [M+Na]+ 467.0042 467.0060 
Sulfabenzamide-PP45 C22H22N2O5S [M+Na]+ 453.1647 453.1673 
Sulfabenzamide-PP46 C22H22N2O5S [M+Na]+ 449.1147 449.1166 
Sulfabenzamide-PP49 C18H16N2O3S2 [M+Na]+ 395.0500 395.0499 
Sulfabenzamide-PP50 C18H16N2O4S [M+Na]+ 379.0729 379.0733 
Sulfabenzamide-PP52 C22H18N2O3S2 [M+Na]+ 445.0657 455.0665 
Sulfabenzamide-PP54 C21H18N2O5S [M+Na]+ 433.0834 433.0838 
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Figure 27. RP- HPLC chromatograms. 
Chromatograms of incubation mixtures of sulfabenzamide with pyrophosphate 
analogues which lead to the NphB catalyzed formation of alkylated sulfabenzamide 
derivatives. 
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NphB mutational studies.  
Based on the analysis of the existing crystal structure of NphB, complexed with geranyl 
S-thiodiphosphate (GSPP) and 1,6-DHN (PDB ID, 1zb6), along with previously 
performed prenyltransferase mutational studies, we speculated altering residues found 
in the prenyl binding pocket would subsequently modify the substrate specificities. [36, 
56] Guided by the mutational studies on TleC, MpnD, and PagF (TleC Phe170 and 
Trp97, MpnD Met159 and Tyr80, PagF Phe222), we therefore focused on key residues 
lining the distal end of the prenyl binding pocket: Met106 and Phe123. [53, 100] To 
evaluate the impact of the size of the side chain, we constructed the M106V variant. 
Further modifications to the prenyl binding pocked were made by construction of a 
double mutant, M106V/F123V. Variant enzymes were assayed against the alkyl-PP 
library with sulfabenzamide (Figure 28D). Both the single and double mutant, M106 
and M106V/F123V, were able to accept GPP as a prenyl donor (M106V/F123V kcat 7.8 
x 10-3 min-1, KM 0.4 mM; M106V 1.5 x 10-3 min-1, KM 0.6 mM ), an activity not present 
in wild-type enzyme when incubated with sulfabenzamide as the acceptor (Figure 28 A-
C). Furthermore, both mutants were able to transfer PP31 (5% and 3.5%) and the 
double mutant accepted PP32, PP33, and PP64 to a small degree (5%, 4%, and 11.5%).  
New activity shown in the NphB mutants was seen when incubated with longer 
pyrophosphate analogues and sulfabenzamide. Although the majority of wild-type 
activity was maintained in the mutants, a decrease in product formation was seen for all 
other reactions. 
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Figure 28. NphB mutation analysis. 
(A) Reverse-phase HPLC analysis of NphB wild-type (bottom) and NphB 
M106V/F123V (top) enzyme assays using sulfabenzamide and GPP/PP29. (B) NMR 
correlations (blue arrow, COSY correlations, black arrow, HMBC correlations) of 
sulfabenzamide-GPP product generated through incubation NphB M106V/F123V. (C) 
Kinetic curves showing the enzyme activities of NphB M106 and M106V/F123V with 
sulfabenzamide and GPP/PP29. (D) Percent conversion of library of alkyl 
pyrophosphate incubated with sulfabenzamide using NphB-WT (blue) and NphB-
M106V (red) and NphB-M106V/F123V (Green) Assays were performed under standard 
condition and incubated for 16hrs. Alkylated sulfabenzamide products marked with an 
asterisk were isolated using HPLC and characterized using NMR 
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Structure characterization of sulfabenzamide products. 
To elucidate the structure of the alkylated sulfabenzamide products, which were 
generated for 12 out of 29 reactions, confirmed by HRMS and RP-HPLC to yield 
products, were scaled up and purified via a semi-preparative RP-HPLC  protocol (See 
method B (HPLC) in Experimental Methods), and subjected to NMR analysis (Table 7). 
Sulfabenzamide products selected for characterization displayed >15% product 
conversion, as determined in the initial analytical reactions, and possess unique 
electronic and structural features, e.g. carbon chain length, conjugated systems, 
cyclization and aromaticity. Specifically, the characterized sulfabenzamide products 
were diversified through the attachment of allylic analogues, DMAPP (PP5), GPP 
(PP29), ethyl and isopropyl DMAPP derivative (PP6 and PP8), as well as two diene 
analogues with C5 and C6 carbon chain length (PP14 and PP16) and two cyclic 
pyrophosphates (PP19 and PP21).  Additionally, two benzylic derivatized 
sulfabenzamide compounds, (PP37 and PP40), and three heterocyclic analogues (PP49, 
PP50 and PP54) were also scaled up for characterization. The resulting purified 
sulfabenzamide products were subjected to 1H and 2D NMR experiments to determine 
the exact position of derivatization on the parent compound. In addition to the 1H 
experiments, all purified sulfabenzamide products have a COSY spectrum; however, 
due to limited available quantities, experiments such as HMBC and HSQC could only 
be performed on PP29, PP8, PP19, PP49, PP50 and PP54. Previous studies have 
indicated that the position of the alkylation was influenced by the specific alkyl donor 
(Chapter 3, [56]); therefore, given the wide variety of structurally characterized 
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alkylated sulfabenzamide products, we expect insight into the regio selectivity and 
specificity of NphB catalyzed reaction. 
We have concluded that all scaled up sulfabenzamide reactions resulted in the 
regiospecific N-alkylation (Figure 29, NMR Table 5) as characterization by NMR 
analysis, including chemical shift values, integration, splitting, and COSY and/or 
HMBC correlations. The 1H NMR of the sulfabenzamide derivatives, when compared to 
sulfabenzamide, revealed that all aromatic protons were accounted for on both rings of 
the parent compound found in the 6.0-8.0ppm range, strongly suggesting an N-
substitution.  Signals corresponding to the two aromatic rings on sulfabenzamide could 
be differentiated by their splitting pattern, as the benzamide ring displays three distinct 
peaks with multiplet splitting pattern integrating to a 2:2:1 ratio whereas the 4-amino 
benzenesufonyl has two proton peaks with a doublet splitting pattern integrating to a 1:1 
ratio.  Assignments of the aromatic proton signals were further supported by the COSY 
spectra showing correlation peaks between the H2a-H3a and H6a-H5a on the 4-amino 
benzenesulfonyl ring as well as correlation peaks between H2b-H3b, H3b-H4b, H4b-
H5b and H5b-H6b on the benzamide ring.  In some cases, the COSY spectra also 
showed correlation between the proton on the amino NH and the H1’ of the substituent 
alkyl or benzyl group.  For the samples with sufficient quantities of purified compound, 
we were able to obtain additional 2D experiments, the 1H – 13C HMBC and 1H -13C 
HSQC spectra were collected, displaying connectivity between H1’ alkyl or benzyl 
group to the C4a of the 4-amino benzenesuflonyl ring, unequivocally confirming the N- 
alkyl addition.   Each scale up reaction was additionally confirmed by HRMS data, 
supporting on the presence of only a mono-alkylated product. These findings verify the 
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novel capabilities of NphB to catalyze the N-alkylation of sulfabenzamide using natural 
donors DMAPP and GPP, and non-native donors including dienes, para-substituted 
benzyl and heterocyclic pyrophosphate donors 
 
Figure 29. Sulfabenzamide derivatives. 
Reverse-phase HPLC analysis of NphB wild-type catalyzed reactions that resulted in 
structure elucidated via NMR and RP-HRMS. 
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NH 12.07, s       8.13, s   8.13, s   
NH 6.15, s (NH2) 
      6.56, s   6.52, s   
1a                 
2a 7.63, d (8.8) 
130.
6 7.78, d (8.9) 129.4 
7.59, d 
(8.4)   
7.62, d 
(8.7)   
3a 6.61, d (8.8) 
112.
7 6.63 d (8.9) 110.1 
6.52, d 
(8.4)   
6.57, d 
(8.7)   
4a       152.7         
5a 6.61, d (8.8) 
112.
7 6.63 d (8.9) 110.1 
6.52, d 
(8.4)   
6.57, d 
(8.7)   
6a 7.63, d (8.8) 
130.
6 7.78, d (8.9) 129.4 
7.59, d 
(8.4)   
7.62, d 
(8.7)   
1b                 
2b 7.83, dd (8.4, 1.3) 
128.
7 
7.79, dd (7.9, 
1.0) 127.3     
7.84, d 
(7.1)   
3b 7.47, dd (8.4, 7.4) 
128.
9 7.60, t (7.9) 127.8 7.36, m    7.40, t (7.1)   
4b 7.60, tt (7.4, 1.3) 
133.
5 
7.47, tt (7.4, 
1.0) 132.1 7.44, m   7.50, m   
5b 7.47, dd (8.4, 7.4) 
128.
9 7.6 127.8     7.40, t (7.1)   
6b 7.83, dd (8.4, 1.3) 
128.
7 7.79 127.3     
7.84, d 
(7.1)   
1’     3.73, d (6.5) 39.9 3.64, dd (6.5, 5.9)   3.67, t (5.7)   
2’     5.26, t (6.5) 120.5 5.22, t (6.5)   5.22, t (5.7)   
3’       137.7         
4’     2.06, m 38.7 1.68, s   1.99, q (7.8)   
5’     2.11, m 25.5 1.69, s   0.96, t (7.8)   
6’     5.07, t (7.1) 123.1     1.68, s   
7’       130.3         
8’     1.57, s 15.8         
9’     1.57, s 15.8         


















































































































(J) δC δH, multi (J) δC δH, multi (J) δC 
δH, multi 
(J) δC 
NH     8.14, s   12.12, s   8.14, brs   
NH     6.56, s   6.54, s   6.37, brs   














44 6.49, d (8.4)   6.59, d (8.7)   6.52, d (8.8) 
110.
8 







44 6.49, d (8.4)   6.59, d (8.7)   6.52, d (8.8) 
110.
8 
6a 7.94, d (8.9) 
127.
71 7.54, d (8.4)   7.63, d(8.7)   7.59, d (8.8) 
129.
49 
1b   124.09           
136.
76 
2b 7.79, dd (8.4,1.3) 
130.
97 
7.84, dd (8.3, 
1.6)   
7.84, dd (8.3, 







9 7.3   
7.42, dd (8.3, 














9 7.30, m   
7.42, dd (8.3, 







97 7.84   
7.84, dd (8.3, 
1.4)   7.86, d (8.0) 
128.
7 
1’ 3.75, d (6.6) 
41.2
4 3.75, t (5.6)   3.75, td(5.7, 1.5)   3.61, d (6.0) 
42.3
5 
2’ 5.30, t (6.7) 
117.
84 
5.79, dt (15,3, 
5.6)   
5.58, dt (15.1, 
5.7)   
5.34, p (4.1, 
2.1)   
3’   146.11 
6.22, dd (15.3, 
10.5)   
6.17, ddt (15.1, 








6.35, dt (16.9, 
10.5)   
6.05, ddd(15.1, 







































































































































NH 12.12, s   6.55, br s   8.41, s   8.3, brs   
NH 6.54, s       6.53, t (5.8)   6.62, t (6.0)   
1a              134.1 
2a 7.60, d (8.4)   
7.50, d 
(8.4)   
7.49, d 
(8.5)   7.53, d (8.7) 
128.6
8 
3a 6.56, d (8.4)   
6.47, d 
(8.4)   
6.46, d 
(8.5)   6.55, d (8.9) 
111.0
2 
4a               150.03 
5a 6.56, d (8.4)   
6.47, d 
(8.4)   
6.46, d 
(8.5)   6.55, d (8.7) 
111.0
2 
6a 7.60, d (8.4)   
7.50, d 
(8.4)       7.53, d (8.7) 
128.6
8 
1b               139.64 
2b 7.85, d (7.7)   
7.85, d 
(7.1)   
7.85, d 





3b 7.39, t (7.6)   
7.27, t 
(7.1)   
7.26, dd 
(7.1, 6.6)   




4b 7.49, m    7.32, t (7.1)   
7.31, t 
(6.6)   




5b 7.39, t (7.6)   
7.27, t 
(7.1)   
7.26, dd 
(7.1, 6.6)   




6b 7.85, d (7.7)   
7.85, d 
(7.1)   
7.85, d 





1’ 3.57, d (5.7)   
4.20, d 
(5.9)   
4.22, d 
(5.8)   
4.45, d 
(4.45) 42.04 
2’                 
3’ 1.94, m   7.25, d (8.1)   
7.21, d 





4’ 1.57, m   6.87, d (8.4)   
7.1, d 





5’ 1.50, m           
7.34, dd 
(5.1,1.3) 125 
6’ 1.95, m   6.87, d (8.4)   
7.1, d 
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Discussion 
The analysis of our in vitro activity assays revealed NphB capable of the successful 
catalytic transfer of several chemically and structurally distinct alkyl-PP onto two 
different aromatic substrates, 1,6-DHN and sulfabenzamide. Remarkably, these results 
indicate a clear donor-dependent alkylation reaction and a novel N-prenylation 





  Sulfabenzamide-PP50 Sulfabenzamide-PP54 
Position δH, multi (J) δC δH, multi (J) δC 
NH 8.29, brs   8.16, brs   
NH 6.45, t (6.0)   6.64, brs   
1a   133.9   132.16 
2a 7.53, d (8.7) 128.65 7.53, dd (8.8) 128.96 
3a 6.56, d (8.8) 110.94 6.51, d (8.9) 110.93 
4a   149.97   150.58 
5a 6.56, d (8.8) 110.94 6.51, d (8.9) 110.93 
6a 7.53, d (8.7) 128.65 7.53, d (8.8) 128.96 
1b   140.79   138.85 
2b 7.87, dd (7.9, 1.4) 128.69 7.86, dd (8.4,1.3) 128.71 
3b 7.27, dd (8.2, 6.5) 127.73 7.30 t, (7.6,7.4) 127.9 
4b 7.33, dd (8.2, 6.5) 129.94 7.36, t (7.5, 7.5) 130.47 
5b 7.27, dd (8.2, 6.5) 127.73 7.30 t, (7.6,7.4) 127.9 
6b 7.87, dd (7.9, 1.4) 128.69 7.86, dd (8.4,1.3) 128.71 
1’ 4.25, d (5.8) 40.07 4.18, d (5.1) 46.26 
2’   153.52   134.13 
3’ 6.29, d (3.2) 107.36 6.89, s 108.08 
4’ 6.36, dd (3.2, 1.8) 110.76 6.82, m 108.5 
5’       146.43 
6’       147.68 
7’     6.83, m 120.63 
8’       5.95, s 
10       169.14 
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sulfabenzamide.  Recently, a donor-dependent acceptor binding mechanism was 
reported for AtaPT from A. terreus NIH2624, wherein a sequential donor and acceptor 
binding order was determined through isothermal titration calorimetry.[53] The alkyl 
donor then acceptor binding order was also proposed for NphB, based on the crystal 
structure complexed with GSPP alone.[54] In the present study, we observed many 
examples of alkyl donors accepted as substrates by NphB when incubated with 1,6-
DHN; however, the same alkyl donors would not result in a product formation using 
sulfabenzamide. Additionally, by employing structural engineering rationale we 
generated the single and double mutants M106V and M106V/F123V, and were able to 
revive the native geranylation capabilities of NphB when incubated with 
sulfabenzamide.  
 
Alkyl-PP donor specificities were revealed by the enzymatic reaction with 1,6-DHN or 
sulfabenzamide.  As seen in the results, a distinction in chain length preference is made 
according to the aromatic acceptor substrate.  For reactions with 1,6-DHN, a minimal 
conversion of 8% was seen with DMAPP, which has a linear length of four carbons; 
whereas, when reacted with sulfabenzamide, a more substantial conversion of 60% was 
observed. It is our understanding that this is the first occurrence of NphB appreciably 
accepting DMAPP as a prenyl donor.  It became apparent that the enzymatic reactions 
with sulfabenzamide loss the ability to transfer longer chain and bulkier analogues.  
GPP and derivatives (PP29/GPP, PP31, PP32, PP65, PP33 and PP34) were solely 
transferred onto 1,6-DHN to varying product yields.   
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To explain these results, we offer the following explanations. NphB has been shown to 
geranlyate 1,6-DHN in three different positions on the naphthalene ring, signifying that 
1,6-DHN must adopt three different orientations in the binding pocket that result in 
product formation.[54] On the bases of complexed crystal structure, 1,6-DHN is 
stabilized within the active site by a significant contribution from the geranyl tail of 
GSPP, and without these interactions, such as the case with DMAPP, 1,6-DHN could 
bind too loosely and therefore be unable to produce any appreciate product.  In the case 
of NphB incubation with sulfabenzamide, the prenylation site resides in the same 
orientation as it would with 1,6-DHN within the active site, however additional 
hydrogen bonding potential and the larger size of the substrate is likely to contribute to 
its increased stability with respect to orientation in the active site in the absence of the 
geranyl tail of GPP. A fixed conformation could also explain the observation of a single 
N- alkylation mode for sulfabenzamide derivatives, a similar relationship between 
larger substrates and a single product have previously been reported for NphB 
reactions.[54] Because the larger prenyl donors could occupy the same space as the 
benzamide moiety of sulfabenzamide in the active site, the steric bulk is believed to 
prevent the binding of sulfabenzamide and therefore the formation of products, as seen 
in our results. The NphB mutants M106V and M106V/F123V relieved steric restrictions 
up the prenyl binding pocket, potentially decreasing the steric hindrance between the 
terminal end of the alkyl donor and benzamide moiety, as the mutants showed higher 
product conversion with longer chained alkyl-PP (Figure 28).  
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In conclusion, NphB demonstrated generous capabilities to transfer diverse unnatural 
and synthetic alkyl donors onto 1,6-DHN as well as the synthetic pharmaceutical drug, 
sulfabenzamide, ultimately generating novel N-alkylated sulfabenzamide derivatives.  
Furthermore, through structure-based enzyme engineering NphB was able to broaden it 
substrate acceptance and generate a geranylated sulfabenzamide derivative.  These 
results implicate the plausibility of prenyltransferases in biotechnologies and expand on 
their catalytic abilities to feasibly generate novel drug derivatives.  
 
Experimental  
Protein Expression and Purification 
The recombinant plasmid, pET-28a containing synthetic genes for NphB bearing N-
terminal His6, was transformed into E. coli Rosetta cells. After overnight growth, 3 mL 
of bacterial culture was transferred to 4 L flasks containing 1.2 L Lauria-Berani medium 
and 50 µg kanamycin ml -1 and were grown at 37°C for approximately 4 h at 220 r.p.m. 
(O.D600 =0.6-0.8). Protein expression was induced by the addition of IPTG (0.5 mM 
final) and continually shaken at 220 r.p.m. for an additional 16-19 h at 20°C.  Bacterial 
cultures were harvested by centrifugation and the resulting cell pellets were 
resuspended in a lysis buffer (50mM NaH2PO4, 200mM NaCl, pH 7.8). Cells were 
lysed by way of sonication on ice 60 times for 10 s (Fisher Scientific Model FB505; 
Thermo Fisher Scientific, Waltham, MA).  In order to remove unwanted cellular debris 
and insoluble protein, the lysed cells were spun down at 16000 r.p.m. for 1 h at 10°C.  
The supernantant, containing the expressed recombinant enzyme with a N-terminal His6 
tag, was purified using Ni Sepharose resin affinity chromatography column (GE 
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Healthcare, USA).  Protein was eluted using 50 mM NaH2PO4, 200 mM NaCl, pH 7.8 
and 500 mM Imidazole. The purified protein was concentrated and introduced to a new 
buffer condition (20 mM Tris-HCl, pH 8, 30 mM NaCl) through centrifugal filtration.  
Purity was evaluated by SDS-PAGE and the resulting protein bands indicate both a high 
grade of purity and the appropriate molecular weight for NphB.  A Bradford assay was 
conducted to conclude a final enzyme concentration using BSA as a standard.  
Site-directed mutagenesis.  The plasmids containing the mutated NphB (M106V, 
M106V/F123V) were constructed by Genescript in a pET-28a vector.  Each mutant 
protein contained an N-terminal His6 and were expressed and purified identically to the 
wild type NphB. 
In vitro Activity Assays 
Analytical Assays. NphB analytical reactions were performed in a final volume of 20ul, 
consisting of 1.2mM pyrophosphate analogues, 1mM sulfabenzamide (Sigma-Aldrich) 
or 1,6 Dihydroxy Napthalene  and 6uM purified NphB in a reaction buffer (25 mM Tris 
buffer pH 8.0, 5 mM MgCl2, 50 mM KCl) and incubated at 35 °C for 16 h.  Reactions 
were terminated through cold methanol quenching followed by centrifugation (10,000 g 
for 30min) to remove precipitated protein. Reaction analysis was completed on RP-
HPLC using method A (general method).  NphB large scale reactions were conducted in 
a volume of 1.2ml or 10ml consisting of 4.16mM pyrophosphate analogues, 6mM 
sulfabenzamide and 0.3mM purified NphB in reaction buffer.  Putative products were 
subsequently isolated by semi-prep HPLC through method B and confirmed by NMR 
and HRMS with positive (+) and/or negative (-) mode. 
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HPLC and NMR methods. HPLC was accomplished using Agilent 1220 system 
equipped with a DAD detector.  Method A (HPLC): To monitor NphB reactions, 
analytical reverse-phase (RP) HPLC employed a Gemini-NX, C-18 (5 µm, 4.6 mm × 
250 mm) column (Phenomenex, Torrance, California, USA) [gradient of 1% B to 10% 
B over 10 min, 10% B to 50% B over 5 min, 50% B to 100% B for 12 min, 100% B to 
1% B over 1 min, 1% B for 7 min (A = ddH2O with 0.1% TFA; B = acetonitrile) flow 
rate = 1 mL min-1; A254/235]. The reaction was monitored by the retention time difference 
between starting material and product. Method B (HPLC): Semi-preparative RP HPLC 
was conducted on a Gemini-NX, C-18 (5 µm, 10 × 250 mm) column (Phenomenex, 
Torrance, California, USA) to purify the Sulfabenzamide analogues [gradient of 1% B 
to 10% B over 10 min, 10% B to 50% B over 5 min, 50% B to 100% B for 12 min, 
100% B to 1% B over 1 min, 1% B for 7 min (A = ddH2O with 0.1% TFA; B = 
acetonitrile) flow rate = 2 mL min-1; A254]. High-resolution mass spectrometric (HRMS) 
data and liquid chromatography mass spectrometric (LCMS) were obtained on Agilent 
6545-QTOF W/1290 HPLC mass spectrometer at the University of Oklahoma, 
Department of Chemistry and Biochemistry. NMR spectra were obtained on Varian 
VNMRS  500 MHz instruments at the NMR facility of the Department of Chemistry 
and Biochemistry of University at the Oklahoma using 99.9% DMSO-d6 with 0.05% 
v/v TMS. 1H, 13C and 31P chemical shifts were referenced to internal solvent 
resonances. Multiplicities are indicated by s (singlet), d (doublet), t (triplet), q (quartet), 
quin (quintet), m (multiplet), and br (broad). Chemical shifts are reported in parts per 
million (ppm) and coupling constants J are given in Hz. All NMR spectra were 
recorded at ambient temperature and processed using MestReNova software. 
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Kinetic characterization sulfabenzamide derivatives for NphB and NphB mutants.  
Specific kinetic measurements involving NphB mutants, sulfabenzamide and GPP were 
accomplished by monitoring product formation on HPLC (254nm). Reactions took 
place in 20ul total volume, including 2mM sulfabenzamide, appropriate amount of 
NphB and various concentrations of GPP (0.05 – 5mM) in a reaction buffer (25 mM 
Tris buffer pH 8.0, 5 mM MgCl2, 50 mM KCl), The reactions were performed at 35°C 
and were stopped by the addition of 30ul cold methanol.  Each reaction was conducted 
in triplicate and optimized through enzyme concentration and reaction time to ensure 
analysis in the linear range. Specific kinetic constants, Km and kcat were determined by 
fitting the data to the Michaelis-Menten equations using non-linear regression analysis 
provided by Prism 5.04 (GraphPad Software, Inc. La Jolla, CA 92037 USA) 
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Chapter 5. Biocatalytic applications of prenyltransferases in drug 
diversification: A proof-of-concept study using FDA approved 
antibiotic, daptomycin 
Introduction  
Daptomycin is produced in Streptomyces roseosporus as a nonribosomally assembled 
lipopeptide and belonging to the group of calcium-dependent antibiotics. [101-103] 
Daptomycin was first discovered in 1980 and has been an FDA approved 
pharmaceutical since 2003 to treat skin infections caused by gram-positive bacteria S. 
aureus, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae 
as well as E. faecalis and in 2006 it was approved for non-topical treatment of 
bacteraemia and endocarditis caused by MSSA and MRSA. [104-110] Additionally, 
daptomycin has rapid bactericidal activity against many resistant gram-positive 
organisms including penicillin-, vancomycin-, and methicillin- resistant bacteria making 
dapyomycin a first-line drug of last resort.[111, 112] Notably, daptomycin cannot be 
used to treat pneumonia and raspatory infections due to inactivation by the pulmonary 
surfactant. [113] The structure of daptomycin is made up of 13 amino acids, six of 
which are non-standard including B-Asn, ornithine (Orn), D-Ala, D-Ser, (2S, 3R)-
methylglutamate (MeGlu ) and kynurenine (Kyn). The macrocylic core contains 10 
amino acids and a ring-closing ester bond between the C-terminal end of Kyn and the 
side chain of Thr. The exocyclic portion of daptomycin protrudes from the ring and 
features a distinct acyl chain attached to Trp. (Figure 30). [103] The exact daptomycin-
mediated bactericidal mechanism remains poorly understood and highly speculative.  
To date it has been suggested that the mode of action involves the interaction between 
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the gram-positive cell membrane and daptomycin, potentially involving insertion into 
the cell membrane in a Ca2+ - dependent action, generating pores and leading to overall 
membrane depolarization and cell death.  It is believed that the pore formation is 
dependent upon the development of daptomycin aggregates facilitated by free Ca2+ .  
[114-117] However, the studies that reported these conclusions were all performed at 
concentrations much greater than the reported MIC values. It can therefore be 
speculated that these events could not perceivably take place in vivo. Additionally, it 
has been proposed that daptomycin inhibits peptidoglycan and/or lipoteichoic acid 
synthesis within the cell although the mechanism is also not understood. Although 
bacterial resistance remains uncommon, resistance in S. aureus, E. faecium and E. 
faecalis are appearing during treatment with increasing frequency. [118-120] The exact 
mechanism of resistance remains unresolved; however, it has been proposed that 
daptomycin resistance in S. aureus could be mediated by increasing the overall positive 
charge of the surface of the cell instigating an electrostatic repulsion of the daptomycin-
Ca2+ complex. The rise in cases of resistant strains prompts interest in developing new 
daptomycin derivatives to further investigate the mechanism of action as well 
developing new drug analogues with increased antibiotic activity. Many strategies have 
been implemented to developed daptomycin analogues including total chemical 
synthesis, chemoenzymatic synthesis and solid phase approaches, focusing on the 
alteration of amino acids, acyl chain length and ornithine derivatives. [101, 121-132] ,In 
order to generate daptomycin derivatives and maintain the overall potent scaffold of the 
molecule, we propose to employ a decorator enzyme to perform late-stage modification 
the natural product. In this study we will use the aromatic prenyltransferase CdpNPT 
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from Aspergill fumigatus to generate alkyl diversified Trp of daptomycin and evaluate 
the antibacterial properties.  
 
Figure 30. Daptomycin structure 
The structure of daptomycin comprised of 13 (numbered in blue) amino acids.  
Research Objectives 
In this study we sought to test the capability of producing daptomycin derivatives using 
chemoenzymatic methodology.  Specifically, we utilized indole prenyltransferase 
CdpNPT, known to accept daptomycin as a substrate, to generate daptomycin analogues 
substituted with diverse alkyl moieties[40]. CdpNPT was found to catalytically transfer 
alkyl groups onto the N1, C2, C5 or C6 position of the tryptophan residue of 
daptomycin. The structural analysis and subsequent in vitro biological activity assays 
revealed a SAR in daptomycin susceptible and resistant strains yielding high 
improvements in the MIC values for some of daptomycin derivatives.  
Contributions 
Syntheses of alkyl pyrophosphates were carried out by Dr. Chandrasekhar Bandari, 
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enzymatic reaction and purification of daptomycin analogs were carried out in part by 
Dr. Singh, Dr. Bandari and me. NMR data collection of daptomycin analogs was done 
at NMRFAM (Madison, WI) by Dr. Marco Tonelli, NMR data analysis and structural 
characterization was performed by Dr. Singh, and reconfirmation of NMR assignments 
was performed by Eric Gardner. Cytotoxicity assay was carried out by Dr. JianLan You. 
I carried out the expression, purification of CdpNPT, RP-HPLC based assessment, 
antibacterial activity assays, and calculation of LogP values. Most of the contents in this 
chapter including text, tables and figures will be directly used for the publication in a 
peer-reviewed journal. 
Results and discussion 
Assaying the alkyl pyrophosphate substrate tolerance of CdpNPT to construct 
daptomycin analogues.  
To explore the ability of CdpNPT to catalyze the differential alkylation of daptomycin, 
we synthesized a 71-member alkyl pyrophosphate donor library (Figure 31). 
Specifically, the alkyl pyrophosphate library includes various carbon chain length (C3-
C15), benzylic analogues, heterocylic analogues, as well as pyrophosphate analogues 
with chemoselective components such as azides and alkynes. For the assay, 
recombinant CdpNPT was expressed and soluble in E. coli containing a N-terminal His6 
tag and cultured in a total of 4L and purified by Ni-NTA affinity chromatography 
resulting in a yield of 48.5 mg mL-1.  Assaying CdpNPT mediated daptomycin 
alkylation revealed the successful transfer of 37 pyrophosphate analogues, including the 
previously determined DMAPP, onto daptomycin (Figure 29).[40] Remarkably, the 
conversion to alkylated daptomycin was >20% for 33 alkyl analogues and >50% for 13 
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alkyl analogues. Overall, we were able to enzymatically produce daptomycin 
derivatives featuring DMAPP analogues (S3-S9, S13-S15, S17-21), cinnamyl analogues 
(S25-S27), GPP analogues (S32, S34, S38), benzyl analogues (S40-S42, S44-S46, S50), 
heterocycle analogue (S53, S54, S57, S58, S60), and chemoselective analogues with 
azido (S62) and akyne groups (S67, S70). Several reactions indicated the formation of 
multiple product isomers, corresponding to different retention times upon HPLC 
analysis, with some reactions displaying as many 4 distinct product peaks (Figure 32). 
In all cases, product formation of daptomycin derivatives was verified through HPLC 
and high-resolution LC-MS (Table 8). 
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Figure 32. Percent Conversion Daptomycin analogues using CdpNPT 
The percent conversion of alkyl-pyrophosphate analogues with daptomycin catalyzed by 
CdpNPT under standard conditions based upon RP-HPLC. The blue, orange, grey and 
yellow colors correspond to different product peaks as seen on the RP-HPLC 
chromatogram, Reactions were performed with 1.2 mM alkyl-pyrophosphate analogue, 
1 mM daptomycin, CdpNPT, 25 mM Tris, 5 mM CaCl2, 50 mM KCl, pH 7.5, 16 h at 35 
°C. No product formation was observed in the absence of CdpNPT or alkyl-
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Figure 33. HPLC chromatograms  
HPLC chromatograms of the CdpNPT catalyzed reaction using synthetic alkyl 
pyrophosphate library with daptomycin. Reactions were analyzed after incubation 
understand conditions for 16hrs at 35°C 
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S3-DAP C76H108N17O26 1674.7646 1674.7670* 4.499 
S4-DAP C77H109N17O26 1687.7724 1688.7753* 4.610 
S5-DAP C77H110N17O26 1688.7802 1688.7813a* 4.424  C77H110N17O26 1688.7802 1688.7824b* 4.49 
 C77H110N17O26 1688.7802 1688.7818c* 4.722  C82H118N17O26 1756.8428 1756.8416d# 4.722 
S6-DAP C78H112N17O26 1702.7959 1702.7978a* 4.641  C78H112N17O26 1702.7959 1702.7973b* 4.79 
S7-DAP C79H114N17O26 1716.8115 1716.8121* 4.852 
S8-DAP C79H113N17O26 1716.8115 1716.8091* 4.783 
S9-DAP C80H115N17O26 1730.8272 1730.8261* 4.780 
S13-DAP C78H109N17O26 1699.7724 1700.7802 4.508 
S14-DAP C77H108N17O26 1686.7646 1686.7638a* 4.564  C82H114N17O26 1752.8115 1752.8094b# 4.713 
S15-DAP C78H110N17O26 1700.7802 1700.7830a* 4.431  C78H110N17O26 1700.7802 1700.7823b* 4.762 
S17-DAP C79H113N17O26 [M+2H]2+ 857.9016 857.9004* 4.688 
S18-DAP C79H112N17O26 1714.7959 1714.7982a* 4.578  C79H112N17O26 1714.7959 1714.7984b* 4.752 
S19-DAP C79H112N17O26 1714.7959 1714.7935 4.750 
S20-DAP C80H114N17O26 1728.8115 1728.8111* 4.835 
S21-DAP C79H112N17O26 1714.7959 1714.7970a* 4.538  C79H112N17O26 1714.7959 1714.7995b* 4.669  C79H112N17O26 1714.7959 1714.7986c* 4.794 
S25-DAP C81H110N17O26 1736.7802 1736.7806* 4.706 
S26-DAP C82H112N17O26 1750.7959 1750.7978* 4.734 
S27-DAP C82H112N17O27 1766.7908 1766.7914* 4.366 
S34-DAP C80H113N17O26 1728.8115 1728.8067* 4.756 
S38-DAP C82H118N17O27 1773.8456 1773.8328 4.521 
S40-DAP C79H107N17O26 1710.7646 1710.7569* 4.536 
S41-DAP C80H110N17O27 1740.7752 1740.7767a* 4.41  C80H110N17O27 1740.7752 1740.7749b* 4.617 
S42-DAP C80H110N17O27 1740.7752 1740.7669* 4.565 
S44-DAP C80H110N17O26 1724.7802 1724.7731* 4.687 
S45-DAP C79H106FN17O26 1728.7552 1728.7498* 4.517 
S50-DAP C81H111N17O28 1770.7857 1770.7799* 4.230 
S54-DAP C77H105N17O27 1700.7439 1700.7363 4.414 
S57-DAP C81H107N17O26S 1766.7367 1766.7290* 4.730 
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S58-DAP C81H107N17O27 1750.7595 1750.7522* 4.708 
S60-DAP C80H107N17O28 1754.7544 1754.7481* 4.459 
S62-DAP C78H111N20O26 1743.7973 1743.7892* 4.621 
 
Derivatization and determination of bioactivity of daptomycin. 
The analytical reactions described above suggest CdpNPT is a permissive and effective 
alkylation catalyst towards daptomycin, which lead us into the investigation of 
antibacterial potency of the daptomycin analogues. Therefore, to explore the 
significance of the derivatization of daptomycin we carried out semi preparative-scale 
reactions involving 10 alkyl pyrophosphates (S5, S6, S7, S14, S15, S18, S20, S21, S25, 
S41). The reactions were purified using reverse phase HPLC where each product peak 
was separated based on retention times.  The resulting purified products were subjected 
to ESI-HMRS and NMR analysis for structure elucidation (Table 8; Figure 35).  NMR 
analysis confirmed N and C alkylation was performed solely on the tryptophan residue 
of daptomycin, as previously reported.[40] Additionally, several regio- and structural 
isomers were identified amongst the purified compounds, some of which were 
inseparable isomeric mixtures. Ultimately, the semi-preparative purification resulted in 
16 distinct daptomycin analogues (DAP1-DAP16) involving N1, C2, C5, C6 alkylation 
of the indole ring (Figure 34 and 37).   
 
Figure 34. CdpNPT catalyzed reaction producing daptomycin derivatives 
CdpNPT catalyzes the alkylation of daptomycin by diversifying the tryptophan (colored 
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Figure 35. Daptomycin derivatives and placement on the indole ring.  
Shown are the 16 different structurally elucidated daptomycin derivatives.  Placement 
on the tryptophan was determined through H1 and 2D NMR analysis.  In some cases, an 
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Table 9. HRMS data of purified alkyl daptomycin analogues 
 
Enzyme Product Chemical Formula Calculated Mass 
Observed 
Mass 
N1-S5-DAP C77H108N17O26 [M-H]- 1686.7651 1686.7659 
N1-S6-DAP C78H110N17O26 [M-H]- 1700.7808 1700.7818 
C5-S6-DAP: C6-S6-DAP C78H110N17O26 [M-H]- 1700.7808 1700.7816* 
N1-S7-DAP: C6-S7-DAP C79H112N17O26 [M-H]- 1714.7964 1714.7978* 
C5-S7-DAP: C6-S7-DAP C79H112N17O26 [M-H]- 1714.7964 1714.7979* 
N1-S21-DAP C79H112N17O26 [M+H]+ 1714.7964 1714.7970 
C6-S21-DAP C79H112N17O26 [M+H]+ 1714.7964 1714.7995 
N1R-S20-DAP C80H112N17O26 [M-H]- 1726.7964 1726.7957 
N1-S20-DAP C80H112N17O26 [M-H]- 1726.7964 1726.7956 
C5-S20-DAP:C6-S20-DAP C80H114N17O26 [M+H]+ 1728.8121 1728.8111* 
C6-S25-DAP C81H108N17O26 [M-H]- 1734.7651 1734.7659 
C2-S14-DAP C77H108N17O26 [M+H]+ 1686.7651 1686.7638 
C2R-S15-DAP C78H108N17O26 [M-H]- 1698.7651 1698.7605 
N1R-S18-DAP C79H110N17O26 [M-H]- 1712.7808 1712.7814 
C2R-S18-DAP C79H110N17O26 [M-H]- 1712.7808 1712.7800 
C5-S41-DAP: C6-S41-DAP C80H108N17O27 [M-H]- 1738.7601 1738.7578* 
DAP C72H102N17O26 [M+H]+ 1620.7182 1620.7177 
*Inseparable mixture of isomers. 
 
DAP1-DA16 were evaluated for antibacterial activity against 4 bacterial species, 
Staphylococcus aureus, Bacillus subtillis, Enterococcus faecalis and Staphylococcus 
epidermidis, including 12 clinical isolates using the micro dilution method (see 
experimental methods) (Table 10). To assess the possibility of improved antibiotic 
susceptibility using daptomycin derivatives, three daptomycin resistant strains were also 
tested, two transposon mutants, S. aureus (SAUSA300 1713 NE573, SAUSA300 1715 
NE1656) as well as hospital acquired E. faecalis S712. S. aureus ATCC 25923 was 
used as a quality control strain and tested with daptomycin to ensure proper techniques 
and analysis.  The MIC value for the parent compound was 0.6 µg ml-1 as recommended 
by the CLSI and FDA (0.12-1.0 µg mL-1). [133, 134]  In order to gauge the relative 
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antibiotic activity, daptomycin was also evaluated against all strains used in this study 
and compared against MICs for derivatives (Figure 36).  Daptomycin showed an MIC 
range of 0.3-16.2µg mL-1 against the clinical isolates, not including daptomycin 
resistant strains. For the daptomycin resistant strains, the parent compound displayed an 
MIC range 16.2->32.4µg mL-1, consistent with the noted high resistance.  C-2 
substituted compounds, such as DAP12, DAP13 and DAP14 display the lowest 
antibacterial activity with MICs ranging from 4.2 - >33.7µg mL-1 , 4.2 – >34.0µg mL-1 
and 2.1 - > 34.3 µg mL-1, respectively.  Amongst the compounds with highest 
antibacterial activity are C5 and C6 substituted, including DAP2, DAP4, DAP5, DAP6, 
and DAP8 with MICs ranging from 0.1-8.5µg mL-1, 0.5-2.7µg mL-1, 0.3-4.3µg mL-1, 
0.1- 6.2µg mL-1, and 0.2-2.2µg mL-1, respectively (Table 10). Interestingly, DAP6 and 
DAP7 are both substituted with alkyl analogue S21 at different positions on the indole 
ring.  DAP6, a C6 substituted compound, displayed up to an 80-fold MIC improvement 
compared to N1 substituted DAP7.  To assess the effect of the lipophilicity of each 
derivative towards the antibacterial activity, logP values of daptomycin and DAP1-
DAP16 were plotted against their corresponding MIC relative to daptomycin MIC[135] 
(Figure 37).  As anticipated, the addition of the alkyl group increases the logP value 
from -0.47 (daptomycin) to 0.25 (DAP11).  A correlation between increasing logP 
values of the daptomycin derivatives and overall MIC improvement is most strongly 
seen with E. faecalis S613 and daptomycin resistant strains.  DAP2, DAP4, DAP6 and 
DAP8 display an impressive 15 – 80-fold improvement over the parent compound. As 
seen in the LogP correlation plots, LogP values are a characteristic of both the alkyl 
group as well as the position on the indole ring (Figure 37). C-2 substituted analogues 
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exhibit the lowest logP values (-0.2 – -0.1) while C-5 and C-6 gave rise to the highest 
logP values (-0.17 – 0.25).  A comparison of MIC and logP for compounds with high 
logP values (0.0 – 0.25), such as DAP11, DAP8, DAP16, and DAP4, did not show any 
direct correlation. However, when tested with the resistant strains DAP16 and DAP11 
had lower improvement despite being C-5/C-6 substituted with logP values similar to 
the most effective analogues. Overall, the properties of the alkyl group and the 
alkylation position on the indole ring influences the antibacterial activity of the 
daptomycin derivatives. These results imply the aromatic moiety could potentially be 
contributing to the bioactivity of these compounds.  Notably, the bacterial strains 
respond differently to the DAP analogues either indicating a different mechanism of 
action or a different cellular environment. 
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bacterial strain.  Fold improvement was found by the ratio of MIC daptomycin/ MIC 
daptomycin derivatives; MIC values found in Table 10. 
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LogP values for daptomycin and daptomycin derivatives were correlated to their MIC 
improvement as compared to daptomycin for each bacterial strain. Gray plots represent 
the daptomycin resistant strains.  LogP values were calculated using ALOGPS.[135] 
 
Nonribosomal peptides represent a highly promising chemical space with great potential 
for pharmaceutical relevance and medical advancement. Among these compounds, 
daptomycin, a clinically approved antibiotic, represents a unique class of macrolactone 
antibiotics. Due to the fact that daptomycin is a highly complex molecule to approach 
synthetically, the chemoenzymatic strategy that we describe is a successful 
methodology to generate tryptophan substituted daptomycin derivatives.  
Our chemoenzymatic strategy involves the utilization of the highly permissive 
prenyltransferase CdpNPT which uniformly transfers an alkyl group onto the indole 
moiety of daptomycin.  Through this strategy we have revealed the transfer of a large 
variety of alkyl groups onto the C5, C6, C2 and N1 position of the indole ring. As 
reported in Table 8, the position of the substitution has a crucial influence on the 
antibacterial behavior of the derivatized compounds.  The C-2 substituted variants 
display a significant increase of MIC values (up to 80-fold) compared to the N1, C-5 
and C-6 substituted compounds. Based on the results of the logP values, the alkylation 
position as well as the substituent affects the overall lipophilicity of the compound.  
In conclusion, through our chemoenzymatic strategy we were able to specifically 
modify the tryptophan of the highly chemically complex natural product daptomycin.  
These daptomycin derivatives show great improvement of MIC values over the parent 
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compound towards clinically isolated strains including highly relevant daptomycin 
resistant strains. Many issues that have arisen with daptomycin could potentially be 
addressed by further synthesis and evaluation of daptomycin analogues such as the ones 
generated here.  
Experimental 
General methods. HPLC analysis was accomplished using Agilent Technologies 1220 
Infinity LC system equipped with a diode array detector. Method A (HPLC): 
Monitoring CdpNPT catalyzed reaction was completed using an analytical reverse-
phase (RP) HPLC Gemini-NX, C-18 (5 µm, 4.6 mm × 250 mm) column (Phenomenex, 
Torrance, California, USA) employing a gradient of 10% B to 55% B over 10 min, 55% 
B to 100%B for 15 min, 10%B for 5 min (A=H2O with 0.1% TFA; B= acetonitrile), 
flow rate = 1mL min-1 ; A280.  Reaction progression was monitored by the different 
retention times between product and starting material.  Method B (HPLC): Semi-
preparative RP HPLC was conducted using a Gemini-NX, C-18 (5 µm, 10 × 250 mm) 
column (Phenomenex, Torrance, California, USA), peak separation and product 
purification was completed using a shallow gradient of 35% B to 55% B in 20 min, 
55% B to 100% B in 3 min, 35%B for 7 min. (A=H2O with 0.05% formic acid; B= 
acetonitrile) flow rate = 2 mL min -1; A280. High-resolution mass spectrometric (HRMS) 
data and liquid chromatography mass spectrometric (LCMS) were obtained on Agilent 
6545-QTOF W/1290 HPLC mass spectrometer at the University of Oklahoma, 
Department of Chemistry and Biochemistry. All logP values were calculated using 
ALOGPS software found in virtual computational chemistry laboratory[135] 
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Prenyltransferase CdpNPT expression and purification. The synthetic gene for 
CpdNPT, bearing an N-terminal His6 tag, was inserted into vector pET-28a and 
transformed into E. coli Rosetta cells. After overnight growth, 3 mL of bacterial culture 
was used to inoculated 1.2 L Lauria-Berani medium containing 50 µg kanamycin mL -1.  
Cultures were grown at 37°C for approximately 4 h at 220 r.p.m. (O. D600 =0.6-0.8). 
Protein expression was induced by the addition of isopropyl b-D-1-
thiogalactopyranoside (IPTG) (0.5 mM final) and continually shaken at 220 r.p.m. for 
an additional 16-19 h at 20°C.  Bacterial cultures were harvested by centrifugation and 
the resulting cell pellets were resuspended in a lysis buffer (50mM NaH2PO4, 200mM 
NaCl, pH 7.8) and stored at -80°C until use. Resuspended cells were thawed then lysed 
by way of sonication on ice 60 times for 10 s. In order separate insoluble and 
undesirable cellular components, lysed cells were centrifuged for 1 h at 10°C at 16000 
r.p.m. The supernatant, containing the expressed recombinant CdpNPT with an N-
terminal His6 tag, was purified using nickel sepharose resin affinity chromatography 
column (GE Healthcare, USA).  Protein was eluted using an imidazole gradient from 
10mM to 500mM in elusion buffer (50 mM NaH2PO4, 200 mM NaCl, pH 7.8). The 
purified protein was concentrated and introduced to a new buffer condition (25 mM 
Tris-HCl, pH 8, 50 mM KCl) using a desalting column (PD-10 desalting column, GE 
healthcare). Eluents were evaluated by SDS-PAGE for purity, concentration was 
determined using NanoDrop One (Thermo Scientific, USA) and the purified protein 
was stored flash frozen in 20µL aliquots at -80°C. 
In-vitro CpdNPT assay with daptomycin.  In vitro CdpNPT analytical reactions with 
daptomycin were performed in a final volume of 20µL, consisting of 1.2mM 
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pyrophosphate analogues, 1mM daptomycin (TCI, TCI America) and 8µM purified 
CdpNPT in reaction buffer (Tris-HCl pH 7.8, 5 mM CaCl2, 50mM KCl) and incubated 
at 35 °C for 16 h. Reactions were terminated by addition of 60µL cold methanol 
followed by centrifugation (10,000 g for 30 min) in order to remove precipitated 
enzyme. Analysis of the reactions was completed on RP-HPLC using method A 
(general method).  For each reaction the percent conversion was calculated by the 
integration of the product peak at 280nm divided by the overall sum of the integrated 
product peak and starting material at 280nm. All enzymatic products were confirmed by 
using ESI-HRMS.   Large scale reactions of daptomycin analogues were performed on a 
10 mL scale consisting of 1mM daptomycin, 1.25mM pyrophosphate analogue, and 
100µM purified CdpNPT in reaction buffer. Putative products were subsequently 
isolated by semi-prep HPLC using method B (general method, above) and confirmed by 
NMR and ESI-HRMS. 
 
Antibacterial assays. All daptomycin analogue stocks were calibrated by absorbance 
(Calibration curve at l= 280nm, Ɛ366 = 4,000 L mol-1 cm-1)[101] and all bioactivity 
assays were conducted in triplicate. The strains for which MICs were determined 
included, thirteen daptomycin sensitive (DapS) and three daptomycin resistant (DapR) 
strains. The DapS strains are: S. aureus (ATCC 25923), methicillin-resistant S. aureus 
ATCC 700787, S. epidermidis ATCC 12228, vancomycin-resistant Enterococcus. 
faecalis ATCC 700802, Bacillus subtilis (ATCC 6051), hetero-vancomycin 
intermediate S. aureus SR220 (BEI product NR-50512), S. aureus, Strain SR1129 (NR-
50506), S. aureus, Strain SR2609 (NR-50507), S. aureus, Strain SR2852 (NR-50508), 
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hetero-vancomycin intermediate S. aureus SR3777 (BEI product NR-50509), hetero-
vancomycin intermediate S. aureus, SR4035 (BEI product NR-50510), and 
Enterococcus faecalis  S613 (HM-334). The DapR strains are S. aureus, Strain JE2, 
Transposon Mutant NE573 (NR-47116), S. aureus JE2, Transposon Mutant NE1656 
(BEI product NR-48198), and Enterococcus faecalis R712 (HM-335). Enterococcus 
Faecalis Strains S613 and R712 were isolated from the blood of a 64- year old 
hemodialysis patient with fatal bactermia.  Strain S613 was isolated from the patient 
before treatment with daptomycin and is reported to be susceptible to daptomycin.  
Strain R712 was isolated from blood drawn after treatment of daptomycin. (Minimum 
inhibitory concentration (MIC) testing against all strains was performed in Mueller-
Hinton Broth (MHB) or Brain Heart Infusion (BHI) broth, for DapS and DapR strains 
respectively, supplemented with 50 mg L-1 of calcium [136, 137] following the  CLSI 
guidelines for broth microdilution methods using inoculum of 1 × 105 – 5 × 105 
CFU/mL.[138] All Dap analogue stocks were made in DMSO. Serial two-fold dilutions 
of the compounds ranged from 20 to 0.16 µM, 5 to 0.039 µM and 1.6 to 0.0125 µM. 
Briefly, the overnight cultures were grown at 35 °C in MHB. Daptomycin and 
daptomycin analogues were serially diluted in MHB followed by inoculation of serially 
diluted media with 10,000 counts of bacteria from the overnight culture. The culture 
plates were incubated with shaking at 35 °C for 20–24 h. Growth was evaluated using 
the absorbance at 600 nm. The lowest concentration causing 80% inhibition microbial 
growth was defined as the MIC. Growth and sterility controls were included in each 
experiment. In addition, two representative gram-negative bacteria E. coli (ATCC 
11775) and P. aeruginosa (ATCC 10145) were included in the activity assays. The 
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cancer cell-line cytotoxicity assays as a measure of general eukaryotic cell toxicity 
employed the human hepatocyte carcinoma cell line HepG2. The cytotoxicity of 
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